Conditions: Mantle Cell Lymphoma Untreated
Keywords: Lenalidomide 15-196
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 49
Healthy volunteers: no

Brief summary:
The purpose of this study is to find out what effects, good and/or bad, the treatment including 1) Lenalidomide-RCHOP, 2) R-HIDAC, and 3) Lenalidomide-Rituximab maintenance has on the participant and their lymphoma.

Detailed description:
Patients will receive lenalidomide 15 mg orally daily on days 1-14 with standard-dose R-CHOP (375 mg/m\^2 intravenous rituximab, 750 mg/m2 intravenous cyclophosphamide, 50 mg/m\^2 intravenous doxorubicin, and 1.4 mg/m2 intravenous vincristine on day 1, and 100 mg prednisone days 1-5 or days 2-6) every 21 days for four cycles.

All patients will receive pegfilgrastim on day 2 of each cycle and aspirin 81 mg orally daily for venous thromboembolism prophylaxis throughout the four cycles.

After four cycles of Len-RCHOP, the patients will undergo restaging PET/CT scans. Patients with evidence of disease progression will be treated off study.

R-HIDAC After lenalidomide-RCHOP phase, patients without evidence of progressive disease will receive rituximab 375 mg/m\^2 day 1 and then patients will be admitted for high-dose cytarabine (HIDAC). Recommended age-adjusted HIDAC doses are as follows: ≤65 years: 3 g/m2 every12 hours X 4 doses; 65-70 years: 2 g/m\^2 every12 hours X 4 doses; \>70 years: 1 g/m\^2 every12 hours X 4 doses. Physician discretion will dictate the choice of HIDAC dose, ranging from 1 g/m\^2 - 3 g/m\^2 every 12 hours X 4 doses.

Patients will receive two cycles of rituximab-HIDAC every 3 weeks. After two cycles of R-HIDAC, the patients will undergo restaging PET/CT scans. Patients with evidence of disease progression will be treated off study.

Len-Rituximab Maintenance After completion of induction chemotherapy with Len-RCHOP and R-HIDAC, patients will begin maintenance phase with lenalidomide and rituximab for 6 months. Lenalidomide will be administered at 15 mg orally daily on days 1-21 of a 28-day cycle for a total of 6 cycles and rituximab maintenance every 8 weeks for a total of 3 treatments.

Arms:
arm 1: Lenalidomide + R-CHOP x 4 cycles R-HiDAC x 2 cycles R-Len maintenance x 6 months. Patients will be followed on active follow up for three years after completion of therapy. After the active followup period, survival, relapse, and new anti-lymphoma therapy information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 6 months until death, loss to follow up or consent withdrawal, whichever comes first.

Interventions: intervention 1: Lenalidomide intervention 2: R-CHOP intervention 3: high-dose cytarabine (HIDAC)
Intervention descriptions: intervention 1: None intervention 2: * Rituximab 375 mg/m\^2 IVPB with premedications Day 1
* Cyclophosphamide 750 mg/m\^2 IVPB Day 1
* Doxorubicin 50 mg/m\^2 IVP Day 1
* Vincristine 1.4 mg/m\^2 IVP (capped at 2 mg) Day 1
* Prednisone 100 mg PO Daily on Days 1-5 or 2-6 intervention 3: None

Protocol document:
Prot_SAP_000.pdf: 
 
Memorial Sloan Kettering Cancer Center 
1275 York Avenue 
New York, New York 10065 
Page 1 of 50 
Version: 7/21/2021 
 
MSK PROTOCOL COVER SHEET 
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide 
Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study 
Principal Investigator/Department: Anita Kumar, MD / Medicine
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 
2 
of 
50 
 
Table of Contents 
1.0 
PROTOCOL SUMMARY AND/OR SCHEMA ........................................................................ 3 
2.0 
OBJECTIVES AND SCIENTIFIC AIMS ................................................................................. 3 
3.0 
BACKGROUND AND RATIONALE ....................................................................................... 4 
4.0 
OVERVIEW OF STUDY DESIGN/INTERVENTION ............................................................ 11 
4.1 
Design .................................................................................................................................... 11 
4.2 
Intervention ............................................................................................................................ 11 
5.0 
THERAPEUTIC/DIAGNOSTIC AGENTS............................................................................. 12 
6.0 
CRITERIA FOR SUBJECT ELIGIBILITY............................................................................. 17 
6.1 
Subject Inclusion Criteria ....................................................................................................... 17 
6.2 
Subject Exclusion Criteria...................................................................................................... 18 
 
Known hypersensitivity to thalidomide or lenalidomide ........................................................ 18 
 
The development of erythema nodosum if characterized by a desquamating rash while 
taking thalidomide or similar drugs. .............................................................................................. 18 
7.0 
RECRUITMENT PLAN ......................................................................................................... 18 
8.0 
PRETREATMENT EVALUATION ........................................................................................ 19 
9.0 
TREATMENT/INTERVENTION PLAN ................................................................................. 20 
10.0 EVALUATION DURING TREATMENT/INTERVENTION .................................................... 31 
11.0 TOXICITIES/SIDE EFFECTS ............................................................................................... 33 
12.0 CRITERIA FOR THERAPEUTIC RESPONSE/OUTCOME ASSESSMENT ...................... 38 
13.0 CRITERIA FOR REMOVAL FROM STUDY ........................................................................ 41 
14.0 BIOSTATISTICS ................................................................................................................... 42 
15.0  RESEARCH PARTICIPANT REGISTRATION AND RANDOMIZATION PROCEDURES43 
15.1 Research Participant Registration......................................................................................... 43 
15.2 Randomization ....................................................................................................................... 43 
16.0 DATA MANAGEMENT ISSUES........................................................................................... 43 
16.1 Quality Assurance.................................................................................................................. 44 
16.2 Data and Safety Monitoring ................................................................................................... 44 
17.0 PROTECTION OF HUMAN SUBJECTS.............................................................................. 44 
17.1 Privacy ................................................................................................................................... 45 
17.2 Serious Adverse Event (SAE) Reporting .............................................................................. 45 
17.2.1............................................................................................................................................. 46 
18.0 INFORMED CONSENT PROCEDURES.............................................................................. 46 
19.0 REFERENCES ...................................................................................................................... 48 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 
3 
of 
50 
 
20.0 APPENDICES ....................................................................................................................... 50 
 
 
1.0 
PROTOCOL SUMMARY AND/OR SCHEMA 
In this phase II study, we aim to improve outcomes for untreated mantle cell lymphoma 
(MCL) patients by incorporating the highly active agent, lenalidomide, to a standard induction 
chemotherapy backbone including RCHOP and high-dose cytarabine. Traditionally, patients 
with MCL have been treated based upon age or transplant-eligibility status with “younger” 
patients receiving multi-agent chemotherapy followed by high-dose therapy and autologous 
stem cell transplant (HDT-ASCT) while “older” patients typically receive less toxic 
chemotherapy combinations, like bendamustine and rituximab. However, this paradigm may 
no longer be applicable in MCL with the advent of highly active, biologically-targeted 
therapies, such as lenalidomide, and emerging data that suggests an unclear benefit of 
consolidation with HDT-ASCT.  In this study, we will enroll both “younger” and “older” 
patients with untreated MCL. Lenalidomide has known clinical activity in both untreated and 
relapsed/refractory MCL. With increasing data demonstrating the benefit of maintenance 
after initial therapy, in this study, patients will receive 6 months of rituximab and lenalidomide 
maintenance therapy. In addition, we will assess early biomarkers for response, including 
PET/CT and minimal residual disease assessment using a novel deep-sequencing platform, 
and correlate these biomarkers with clinical outcomes. In particular, we are interested in 
assessing what proportion of patients convert to MRD- and PET-negativity after each phase 
of therapy, Len-RCHOP, R-HiDAC, and after Len-R maintenance, to assess the kinetics and 
depth of response with the three phases of treatment. The primary outcome in the study will 
be 3-year progression-free survival and the study will enroll a total of 45 patients.  
 
 
2.0 
OBJECTIVES AND SCIENTIFIC AIMS 
Primary Objective 
 
Determine the 3-year progression-free survival (PFS) of the primary treatment program (Len-
RCHOPR-HiDACR-Len maintenance) 
Secondary Objectives 
 
Assess the 3-year PFS in different clinical risk subgroups, specified below: 
Lenalidomide    
+  
R-CHOP 
x 4 cycles 
R-HiDAC  
x 2 cycles 
R-Len maintenance 
x 6 months 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 
4 
of 
50 
 
o Low Risk: Ki-67<10% 
o Intermediate Risk: Ki-67 10-30% 
o High Risk: Ki-67≥30% or blastic/blastoid/pleomorphic morphology 
 
Assess if the mantle cell international prognostic index (M-IPI) is prognostically significant 
(correlated with PFS and OS) with this treatment program.  
 
Assess the rate of PET-negativity (Deauville 1, 2, or 3) at various time points and correlate 
with outcome (PFS). Time points include after lenalidomide-RCHOP chemotherapy, after R-
HiDAC therapy, and at the conclusion of maintenance therapy. 
 
Evaluate MRD status using a novel deep-sequencing platform at various time points and 
correlate with outcome (PFS). Time points include baseline, after lenalidomide-RCHOP 
chemotherapy, after R-HiDAC therapy, at the conclusion of maintenance therapy, and 6 
months after completion of Len-R maintenance.   
 
Assess the 3-year overall survival (OS) 
Exploratory Objectives 
 
Collect serum and peripheral blood mononuclear cells to store in MSKCC tissue bank for 
future correlative studies. Time points will be the same as MRD collection time points 
(baseline, after lenalidomide-RCHOP chemotherapy, after R-HiDAC therapy, at the 
conclusion of maintenance therapy, and 6 months after completion of Len-R maintenance).    
 
3.0 
BACKGROUND AND RATIONALE 
Mantle Cell Lymphoma 
Mantle cell lymphoma (MCL) is an uncommon B-cell Non-Hodgkin lymphoma, comprising 
approximately 6-8% of all Non-Hodgkin lymphomas.1 Mantle cell lymphoma often presents 
with advanced stage disease and common sites of extranodal involvement include the bone 
marrow or GI tract. The median age of presentation for mantle cell lymphoma is 68 years and 
more commonly presents in men versus women.  
 
Morphologically, MCL is comprised of small to intermediate sized cells with a characteristic 
immunophenotype of CD5+, CD10-, BCL6-, CD20+, CD23-, CD43+, and cyclin D1+. There 
are different morphologic variants of MCL including blastoid, pleomorphic, small cell, and 
marginal zone-like variants. Blastoid and pleomorphic variants are composed of larger cells, 
similar to lymphoblasts, and are associated with poor clinical outcomes.2 Mantle cell 
lymphoma is classically characterized by the presence of the reciprocal chromosomal 
translocation t(11;14) between the proto-oncogene CCND1 and the immunoglobulin heavy 
chain (IgH) locus.3 This translocation leads to the deregulation of the gene CCND1 and to the 
overexpression of its protein product cyclin D1, an important regulator of the G1-S phase 
transition of the cell cycle. There are rare cases of cyclin D1and t(11;14) negative MCL. 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 
5 
of 
50 
 
These cases typically over express cyclin D2 or D3 and can be associated with 
rearrangements involving the CCND2 gene.4,5 Recently, expression of the transcription factor 
SOX11 has been described to be present in the majority of cases of conventional MCL, as 
compared to indolent MCL which lacks SOX11 expression, and the presence of SOX11 
expression can be a useful diagnostic tool in cyclin D1 negative cases.6,7       
 
Prognostic Impact of Proliferative Index 
 
The clinical behavior of mantle cell lymphoma is highly variable.  A clinical prognostic score 
called the mantle cell international prognostic index (M-IPI) comprised of four clinical 
baseline characteristics including age, performance status, lactate dehydrogenase level, and 
white blood cell count is an effective risk stratification tool in MCL, recently validated 
demonstrating the 5-year overall survival rates in low, intermediate, an high-risk groups to be 
83, 63, and 34%.8,9 An important biologic prognostic marker in MCL is increased cell 
proliferation. Gene expression profiling defined a "proliferation signature" that is associated 
with inferior survival in MCL.10  Immunohistochemistry tests that are routinely applicable in 
the clinical setting for MIB-1 expression or Ki-67 proliferative index can also provide an 
estimate of the cell proliferation and have been shown to have prognostic impact in multiple 
studies.11,12 For example, in the 2nd Nordic MCL trial (MCL-2) of rituximab-maxi-CHOP 
alternating with rituximab-high-dose cytarabine followed by high dose therapy and stem cell 
transplant, event-free survival was significantly different when comparing groups of patients 
defined by Ki-67 index <10%, 10-29%, and >29%, see figure below.11 Visual estimation of Ki-
67 is subject to interobserver variability and a study determining the proliferative index by 
quantitative analysis also found that Ki-67 was a powerful prognostic tool with a Ki-67 cut-off 
of 30% defining risk groups with statistically significant differences in PFS and OS.12  
Based on these data, we will plan to compare outcomes with our novel treatment program 
across prognostically significant clinical risk groups including 1) low risk: Ki-67<10%, 2) 
intermediate risk: Ki-67 10-30%, and 3) high risk: Ki-67≥30% or blastic/blastoid/pleomorphic 
morphology. In particular, we are interested in assessing whether the addition of 
lenalidomide will improve outcomes for the poor-risk group defined by elevated proliferative 
index.  
Induction chemotherapy for MCL 
Traditionally, patients with MCL have been separated into two groups “younger” or 
“transplant-eligible” versus “older” or “transplant-ineligible.” These two groups have been 
treated differently with “younger” patients receiving multi-agent chemotherapy followed by 
HDT-ASCT while “older” patients typically receive less toxic chemotherapy combinations, like 
R-CHOP followed by maintenance rituximab or bendamustine and rituximab. However, this 
paradigm may no longer be applicable in MCL, particularly with the development of novel 
therapies and with growing evidence that maintenance therapy may be equivalent to HDT-
ASCT.   
Cytarabine is a highly active drug in MCL and for the proposed treatment program it was 
important to ensure that high-dose cytarabine was included in the induction chemotherapy 
program. The addition of cytarabine to induction chemotherapy for younger mantle cell 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 
6 
of 
50 
 
lymphoma patients has been associated with improvements in progression free and overall 
survival in multiple studies. The R-HyperCVAD regimen with alternating high dose cytarabine 
and methotrexate demonstrated a high CR rate of 87% and with median follow up of 8.3 
years, the median time to treatment failure among patients younger than 65 years was 5.9 
years and median OS not yet reached.13,14 Another treatment program including high dose 
cytarabine was the Nordic MCL-2 trial that treated patients with augmented RCHOP 
alternating with R-high-dose cytarabine followed by HDT-ASCT in responding patients.11 The 
6-year OS, EFS, and PFS were 70%, 56%, and 66% respectively. Updated results with 
median observation time of 6.5 years, yielded a median EFS of 7.4 years and median OS 
was not reached.15 A similar phase II trial from the Groupe d'Etude des Lymphomes de 
l'Adulte utilized R-DHAP instead of R-high-dose cytarabine in an induction chemotherapy 
regimen consisting of sequential R-CHOP/R-DHAP followed by HDT-ASCT.16 This study 
reported an ORR of 95% with median EFS of 6.9 years and a 75% survival rate at 5 years. 
Finally, a randomized study from the EU MCL Younger Network reported at American 
Society of Hematology (ASH) 2012 conference, definitively compared RCHOPx6 cycles 
induction chemotherapy to cytarabine-containing alternating RCHOPx3 cycles and 
RDHAPx3 cycles induction chemotherapy and found that the RDHAP induction 
chemotherapy arm was associated with improved CR rate, TTF, and OS.17 In this study, 
responding patients in both arms received consolidation with HDT-ASCT. After a median of 
51 months, time to treatment failure (TTF) was longer in the DHAP-containing arm (46 vs 88 
months; p=0.038, HR 0.68) and OS was also superior (not reached vs 82 months, p=0.045). 
A recent MSKCC trial (11-095) utilized a cytarabine-containing induction chemotherapy 
backbone with 4 cycles of dose-dense RCHOP followed by 2 cycles of R-high-dose-
cytarabine with excellent preliminary results. For the current study, we plan to add 
lenalidomide to a cytarabine-containing induction chemotherapy backbone consisting of 4 
cycles of RCHOP chemotherapy followed by 2 cycles of high-dose cytarabine.  
Lenalidomide in Mantle Cell Lymphoma  
Lenalidomide is a proprietary IMiD® compound of Celgene Corporation.  IMiD® compounds 
have both immunomodulatory and anti-angiogenic properties which could confer antitumor 
and antimetastatic effects.  Lenalidomide has been demonstrated to possess anti-angiogenic 
activity through inhibition of bFGF, VEGF and TNF-alpha induced endothelial cell migration, 
due at least in part to inhibition of Akt phosphorylation response to bFGF.18  In addition, 
lenalidomide has a variety of immunomodulatory effects.  Lenalidomide stimulates T cell 
proliferation, and the production of IL-2, IL-10 and IFN-gamma, inhibits IL-1 beta and IL-6 
and modulates IL-12 production.19   
Although the exact antitumor mechanism of action of lenalidomide is unknown, a number of 
mechanisms are postulated to be responsible for lenalidomide’s activity against multiple 
myeloma.  Lenalidomide has been shown to increase T cell proliferation, which leads to an 
increase in IL-2 and IFN-gamma secretion.  The increased level of these circulating 
cytokines augment natural killer cell number and function, and enhance natural killer cell 
activity to yield an increase in multiple myeloma cell lysis.20  In addition, lenalidomide has 
direct activity against cancer cells and induces apoptosis or G1growth arrest in multiple 
myeloma cell lines.21 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 
7 
of 
50 
 
Lenalidomide is an immunomodulatory agent demonstrating antiproliferative effects in MCL. 
Several studies demonstrated promising activity with single-agent oral lenalidomide as well 
as lenalidomide and rituximab for the treatment of relapsed/refractory MCL. Lenalidomide 
was administered at a dose of 25 mg daily in a subset of 57 relapsed/refractory MCL patients 
included in the NHL-003 study and was associated with an ORR of 35% with a median 
duration of response of 16.3 months after approximately 20 months median follow up.22 The 
larger international, multi-center, phase II EMERGE study of single-agent lenalidomide in 
patients who relapsed after or were refractory to bortezomib demonstrated an ORR of 28% 
(7.5% CR/CRu) with a similar median duration of response of 16.6 months.23 This study led 
to the FDA approval of lenalidomide in MCL patients whose disease relapsed or progressed 
after two prior therapies, one of which included bortezomib. In combination with rituximab, 
lenalidomide was well-tolerated and associated with improved response rates, ORR 57% 
(36% CR/CRu).24  
Lenalidomide has also been used for the upfront treatment of mantle cell lymphoma. A 
recent study reported by Ruan et al at the ASH 2014 conference included data from 38 
previously untreated advanced stage MCL patients treated with induction and maintenance 
lenalidomide and rituximab.25,26 During the induction phase, lenalidomide was administered 
at 20 mg daily on days 1-21 of a 28-day cycle for a total of 12 cycles, with dose escalation to 
25 mg daily if tolerated.  Rituximab was administered weekly x 4 during cycle 1, then once 
every 2 months, for a total of 9 doses.  During the maintenance phase which starts with cycle 
13, lenalidomide is administered at 15 mg daily on days 1-21 of a 28-day cycle, with 
rituximab maintenance every 2 months until progression of disease. The majority of patients 
had favorable disease biology with Ki67 index of <30% in 68% of patients (26/38). The ORR 
for all patients was 84.2% with 52.6% achieving a CR. With median follow up of 24 months, 
the estimated 2-year PFS rate is 83.9% and median PFS was not reached. The depth of 
responses improved over time with an increased number of patients achieving a complete 
response by 12 months compared with 3 months. In this study, neither MIPI score nor Ki67 
index correlated with response. The preliminary data from this study is very promising, 
showing high response rates and an excellent 2-year PFS with the combination of 
lenalidomide and rituximab for the initial treatment of mantle cell lymphoma.  
Lenalidomide-RCHOP 
Given the excellent activity of lenalidomide in mantle cell lymphoma both for newly 
diagnosed patients as well as in relapsed, refractory patients, incorporation of lenalidomide 
into a standard chemotherapy backbone for untreated mantle cell lymphoma is likely to result 
in the increased efficacy of the induction program. We hypothesize that the induction 
regimen of Len-RCHOP followed by R-HIDAC will result in a higher complete response rate 
and higher proportion of patients with absence of minimal residual disease, as well as 
improvements in PFS and OS.  
Lenalidomide has been safely combined with RCHOP in a phase 1 studies of B-cell Non-
Hodgkin lymphomas and in two large phase 2 trials in diffuse large B-cell lymphoma 
(DLBCL).27-30 Two different dosing schedules for the lenalidomide have been used in DLBCL: 
1) lenalidomide 15mg orally daily on days 1-14 and 2) lenalidomide 25 mg orally daily on 
days 1-10. Although both were safe, the lenalidomide dose of 15 mg days 1-14 versus 25 mg 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 
8 
of 
50 
 
days 1-10 was associated lesser myelosuppression (22% vs. 75% grade 4 neutropenia; 13% 
vs. 44% grade 3 and 4 thrombocytopenia; 4% vs. 9.4% febrile neutropenia, respectively).29 
The VTE rates were low in both studies, range 1.6 – 4%. Therefore, we plan to use the 
dosing schedule of lenalidomide 15mg orally daily on days 1-14 in conjunction with standard 
RCHOP. In addition, all patients with receive pegfilgrastim support and aspirin VTE 
prophylaxis.   
Maintenance therapy in MCL 
In the current study, after completion of induction chemotherapy, patients will receive 
maintenance therapy with lenalidomide and rituximab. Lenalidomide and rituximab 
maintenance therapy was effectively applied in the aforementioned study by Ruan et al and 
there are a growing number of studies that underscore the important of maintenance therapy 
in MCL. Although several phase II studies that have supported the role of HDT-ASCT after 
induction chemotherapy in younger patients with MCL, there is no phase III randomized trial 
data to support the use of HDT-ASCT in first remission in MCL. Furthermore, there is data to 
suggest that HDT-ASCT may be deferred to a later time point in the disease course of MCL. 
A recent registry study from the Center for International Blood and Marrow Transplant 
Research demonstrated that HDT-ASCT performed at a later time point, not after first 
remission, is an effective strategy resulting in a 5-year overall survival of 44%.31 A recent 
study reported at ASH 2014 of the first interim analysis of the phase III randomized Lyma 
Trial showed a significantly improved EFS and PFS after rituximab maintenance versus 
observation. In this study, patients were treated with R-DHAP x 4 cycles and if CR/PR, then 
patients received HDT-ASCT with subsequent randomization to rituximab maintenance 
versus observation.  Finally, there are several studies that have demonstrated the efficacy of 
maintenance therapy after induction chemotherapy in mantle cell lymphoma. In the EU MCL 
Elderly phase III study, patients ≥ 60 years of age underwent two randomizations: first to R-
FC versus R-CHOP chemotherapy and next to maintenance therapy with rituximab or 
interferon alpha until progression.32 Overall survival was significantly improved in the RCHOP 
versus R-FC arm, and among responding patients who received RCHOP, administration of 
maintenance rituximab was associated with improved overall survival with a 4-year overall 
survival of 87%. These results for RCHOP followed by maintenance rituximab are among the 
best outcomes reported for the upfront treatment of MCL in the elderly and suggest that the 
maintenance phase is important for prolonging PFS and OS and likely improves the depth of 
response after initial therapy. Another study including maintenance therapy for untreated 
MCL is the Eastern Cooperative Oncology Group phase 2 study of rituximab, bortezomib, 
modified hyper-cyclophosphamide, doxorubicin, vincristine, dexamethasone (VcR-CVAD) 
induction chemo immunotherapy with maintenance rituximab for 2 years.33 Seventy-five 
patients were included and transplant-eligible patients had the option of HDT-ASCT 
consolidation instead of maintenance rituximab. The primary end point was the CR rate to 
VcR-CVAD. The ORR was 95% and a CR was achieved in 68% of patients. After a median 
follow-up of 4.5 years, 3-year PFS and OS were 72% and 88%, respectively. No substantial 
difference in PFS or OS was observed between patients treated with maintenance rituximab 
(n = 44) vs HDT-ASCT (n = 22). Although the study was not designed or powered to 
compare maintenance rituximab and HDT-ASCT, these data raise the possibility that a 
maintenance phase post-induction may be equivalent to HDT-ASCT.34 Taken together, these 
data suggest that maintenance therapy is highly efficacious in MCL and that HDT-ASCT, 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 
9 
of 
50 
 
particularly in light of its associated toxicities, may not be a necessary component of initial 
therapy for MCL patients.  
The lenalidomide maintenance dose of 15 mg day on days 1-21 of 28-day cycle with 
rituximab every 2 months is the same maintenance dose used in the Weill Cornell Medical 
College study of untreated advanced stage MCL patients with induction and maintenance 
lenalidomide and rituximab.25 Lenalidomide maintenance has been extensively studied in 
multiple myeloma and the maintenance dose ranges from 10-15 mg days 1-21 of a 28-day 
cycle continued indefinitely post-ASCT and is generally well-tolerated and associated with 
prolonged time to disease progression.35,36 The optimal duration of maintenance therapy is 
unclear in MCL, and, therefore, we are interested in studying an abbreviated maintenance 
period of 6 months and utilizing MRD assessments to gain insight into the optimal duration of 
lenalidomide-rituximab based upon conversion from MRD-positivity to negativity.  
Minimal Residual Disease in MCL 
Several strategies for the detection of minimal residual disease in lymphoid malignancies 
have been developed. A molecular marker for MRD in B-cell lymphomas is the presence of a 
unique immunoglobulin heavy chain gene rearrangement associated with a malignant clone 
(clonotypic DNA sequence). Allele-specific oligonucleotide PCR (ASO-PCR) amplification of 
immunoglobulin genes has been previously employed, however, a novel DNA sequencing-
based technique for detecting MRD has been developed with advantages over ASO-PCR.  
The Sequenta LymphoSIGHT™ platform is a high-throughput DNA sequencing method that 
can detect minimal residual disease (MRD) of lymphoid malignancies in peripheral blood that 
has a higher sensitivity of one lymphoma cell per million leukocytes, efficient turn-around 
time, and the ability to detect and monitor multiple clones.37,38 
MRD detection has been found to be prognostically significant in MCL.39,40 Using the ASO-
PCR technique, MCL patients treated on 2 randomized trials (MCL Younger and Elderly) had 
MRD status assessed after induction therapy and after HDT/ASCT (MCL Younger) or during 
maintenance therapy (MCL Elderly).39 Achievement of molecular remission (MRD-negative) 
after induction therapy and HDT/ASCT was associated with significantly improved 
progression-free survival.    
In this study, we plan to test MRD status using the Sequenta LymphoSIGHT™ platform after 
lenalidomide-RCHOP chemotherapy, after R-HiDAC therapy, at the conclusion of 
maintenance therapy, and 6 months after completion of Len-R maintenance.   
Adaptive Biotechnologies will be using the data to seek regulatory approval and development 
of the assay for treatment purposes.  
 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 10 of 50 
 
 
Interim PET-CT in MCL 
Achievement of a negative PET-scan after induction chemotherapy prior to consolidation with 
HDT/ASCR has been shown to be prognostically significant. In the MCL-3 study of R-maxi-
CHOP alternating with R-high-dose Ara-C followed by Zevalin-ASCT, 77% of patients had a 
PET-CT scan performed after induction chemotherapy and interpreted using the Deauville 5-
point scale with Deauville 1-3 defined as negative. In this study, 85.6% (107/125) patients 
achieved a negative PET-scan and these patients had significantly improved PFS compared 
to patients with an interim PET-positive scan, 4- year PFS of 78% versus 27%, respectively 
(p<0.001).    
In this study, we plan to obtain PET-CT at baseline, after lenalidomide-RCHOP 
chemotherapy, after R-HIDAC therapy, and at the conclusion of Len-R maintenance therapy. 
The PET-CT scans will be interpreted using the Deauville 5-point scale.  
 
Based on these data, we will plan to compare outcomes with our novel treatment program 
across prognostically significant clinical risk groups including 1) low risk:Ki-67<10%, 2) 
intermediate risk: Ki-67 10-30%, and 3) high risk: Ki-67≥30% or blastic/blastoid/pleomorphic 
morphology. In particular, we are interested in assessing whether the addition of 
lenalidomide will improve outcomes for the poor-risk group defined by elevated proliferative 
index.  
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 11 of 50 
 
 
4.0 
OVERVIEW OF STUDY DESIGN/INTERVENTION 
4.1 
Design 
This is a phase II clinical trial at MSKCC for mantle cell lymphoma patients previously 
untreated with systemic therapy. This will include both “younger” / transplant-eligible patients 
as well as “older” / transplant-ineligible patients. Patients will be treated with three phases of 
treatment: lenalidomide + RCHOP, rituximab + high-dose cytarabine, and lenalidomide + 
rituximab maintenance. The treatment schema is shown below:  
 
4.2 
Intervention 
R-CHOP 
Patients will receive lenalidomide 15 mg orally daily on days 1-14 with standard-dose R-
CHOP (375 mg/m2 intravenous rituximab, 750 mg/m2 intravenous cyclophosphamide, 50 
mg/m2 intravenous doxorubicin, and 1.4 mg/m2 intravenous vincristine on day 1, and 100 mg 
prednisone days 1-5 or days 2-6) every 21 days for four cycles.  
All patients will receive pegfilgrastim on day 2 of each cycle and aspirin 81 mg orally daily for 
venous thromboembolism prophylaxis throughout the four cycles.  
After four cycles of Len-RCHOP, the patients will undergo restaging PET/CT scans. Patients 
with evidence of disease progression will be treated off study.   
R-HIDAC 
After lenalidomide-RCHOP phase, patients without evidence of progressive disease will 
receive rituximab 375 mg/m2 day 1 and then patients will be admitted for high-dose 
cytarabine (HIDAC). Recommended age-adjusted HIDAC doses are as follows: ≤70 years: 2 
g/m2 every12 hours X 4 doses and >70 years: 1 g/m2 every12 hours X 4 doses. Physician 
discretion will dictate the choice of HIDAC dose, ranging from 1 g/m2 – 2 g/m2 every 12 hours 
X 4 doses.   
Patients will receive two cycles of rituximab-HIDAC every 3 weeks. After two cycles of R-
HIDAC, the patients will undergo restaging PET/CT scans. Patients with evidence of disease 
progression will be treated off study.   
Len-Rituximab Maintenance 
Lenalidomide    
+  
R-CHOP 
x 4 cycles 
R-HiDAC  
x 2 cycles 
R-Len maintenance 
x 6 months 
Memorial Sloan Kettering Cancer Center
 
x 6 months


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 12 of 50 
 
After completion of induction chemotherapy with Len-RCHOP and R-HIDAC, patients will 
begin maintenance phase with lenalidomide and rituximab for 6 months. Lenalidomide will be 
administered at 15 mg orally daily on days 1-21 of a 28-day cycle for a total of 6 cycles and 
rituximab maintenance every 8 weeks for a total of 3 treatments.  
 
5.0 
THERAPEUTIC/DIAGNOSTIC AGENTS 
5.1  REVLIMID® 
REVLIMID®  (lenalidomide), a thalidomide analogue, is an immunomodulatory agent with anti-
angiogenic properties.  The chemical name is 3-(4-amino-1-oxo 1,3-dihydro -2H-isoindol-2-
yl) piperidine-2,6-dione and it has the following chemical structure:  
Chemical Structure of Lenalidomide 
 
 
3-(4-amino-1-oxo 1,3-dihydro-2H-isoindol-2-yl) piperidine-2,6-dione 
The empirical formula for lenalidomide is C13H13N3O3, and the gram molecular weight 
is 259.3.  
Lenalidomide is an off-white to pale-yellow solid powder. It is soluble in organic 
solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in 
organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, 
ranging from about 0.4 to 0.5 mg/ml. Lenalidomide has an asymmetric carbon atom and can 
exist as the optically active forms S(-) and R(+), and is produced as a racemic mixture with a 
net optical rotation of zero. 
5.1.1 Clinical Pharmacology: 
Mechanism of Action:  
The mechanism of action of lenalidomide remains to be fully characterized. Lenalidomide 
possesses immunomodulatory and antiangiogenic properties.  Lenalidomide inhibited the 
secretion of pro-inflammatory cytokines and increased the secretion of anti-inflammatory 
cytokines from peripheral blood mononuclear cells.  Lenalidomide inhibited cell proliferation 
with varying effectiveness (IC50s) in some but not all cell lines.  Of cell lines tested, 
lenalidomide was effective in inhibiting growth of Namalwa cells (a human B cell lymphoma 
cell line with a deletion of one chromosome 5) but was much less effective in inhibiting 
growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 
5) and other cell lines without chromosome 5 deletions.  Lenalidomide inhibited the 
expression of cyclooxygenase-2 (COX-2) but not COX-1 in vitro.   
5.1.2 Pharmacokinetics and Drug Metabolism 
N
N
H
O
O
O
NH2
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 13 of 50 
 
 
Absorption: 
Lenalidomide, in healthy volunteers, is rapidly absorbed following oral administration with 
maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. 
Co-administration with food does not alter the extent of absorption (AUC) but does reduce 
the maximal plasma concentration (Cmax) by 36%. The pharmacokinetic disposition of 
lenalidomide is linear. Cmax and AUC increase proportionately with increases in dose. 
Multiple dosing at the recommended dose-regimen does not result in drug accumulation. 
Pharmacokinetic analyses were performed on 15 multiple myeloma patients treated in the 
phase I studies.  Absorption was found to be rapid on both Day 1 and Day 28 with time to 
maximum blood levels ranging from 0.7 to 2.0 hours at all dose levels (5mg, 10mg, 25mg, 
and 50mg).  No plasma accumulation was observed with multiple daily dosing.  Plasma 
lenalidomide declined in a monophasic manner with elimination half-life ranging from 2.8 to 
6.1 hours on both Day 1 and 28 at all 4 doses.  Peak and overall plasma concentrations were 
dose proportional over the dosing range of 5mg to 50mg.21  Exposure (AUC) in multiple 
myeloma patients is 57% higher than in healthy male volunteers.  
 
Pharmacokinetic Parameters 
 
Distribution 
 
In vitro (14C)-lenalidomide binding to plasma proteins is approximately 30%. 
 
Metabolism and Excretion 
The metabolic profile of lenalidomide in humans has not been studied. In healthy volunteers, 
approximately two-thirds of lenalidomide is eliminated unchanged through urinary excretion. 
The process exceeds the glomerular filtration rate and therefore is partially or entirely active.  
Half-life of elimination is approximately 3 hours. Supplier(s)Celgene Corporation will supply 
Revlimid® (lenalidomide) to study participants at no charge through Celgene’s Revlimid Risk 
Evaluation and Mitigation Strategy™ (REMS) (formerly known as RevAssist® Program).  
Dosage formLenalidomide will be supplied as capsules for oral administration.  
PackagingLenalidomide will be shipped directly to patients or to the clinic site for IND 
studies.   Bottles will contain a sufficient number of capsules for one cycle of dosing.    
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 14 of 50 
 
Labeling 
Lenalidomide supplies are dispensed in individual bottles of capsules.  Each bottle will 
identify the contents as study medication.  In addition, the label will bear Celgene’s name, 
quantity contained and the standard caution statement as follows:  “Caution: New drug - 
Limited by Federal law to investigational use.” Lenalidomide should not be handled by FCBP 
unless wearing gloves.  
The study drug label must be clearly visible.  Additional labels must not cover the Celgene 
label. 
Receipt of study drug 
The Investigator or designee is responsible for taking an inventory of each shipment of study 
drug received, and comparing it with the accompanying study drug accountability form.  The 
Investigator will verify the accuracy of the information on the form, sign and date it, retain a 
copy in the study file, and return a copy to Celgene or its representative.   
Storage 
At the study site, all investigational study drugs will be stored in a locked, safe area to 
prevent unauthorized access. 
Lenalidomide should be stored at room temperature away from direct sunlight and protected 
from excessive heat and cold.     
Unused study drug supplies 
Celgene will instruct the Investigator on the return or destruction of unused study drug.  If any 
study drug is lost or damaged, its disposition should be documented in the source 
documents.  Study drug supplies will be retained at the clinical site pending instructions for 
disposition by Celgene.  Patients will be instructed to return empty bottles or unused 
capsules to the clinic site.   
Special Handling Instructions 
Females of childbearing potential should not handle or administer lenalidomide unless they 
are wearing gloves. 
 
5.1.3  Prescribing Information  
Lenalidomide (Revlimid®) will be provided to research subjects for the duration of their 
participation in this trial at no charge to them or their insurance providers.  Lenalidomide will 
be provided in accordance with the  Celgene Corporation’s Revlimid REMS® program.  Per 
standard Revlimid REMS® program requirements,  all physicians who prescribe lenalidomide 
for research subjects enrolled into this trial, and all research subjects enrolled into this trial, 
must be registered in, and must comply with, all requirements of the Revlimid REMS® 
program.   
Drug will be shipped on a per patient basis by the contract pharmacy to the clinic site for IND 
studies. Only enough lenalidomide for one cycle of therapy will be supplied to the patient 
each cycle. 
Pregnancy Testing    
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 15 of 50 
 
Must follow pregnancy testing requirements as outlined in the Revlimid REMS® program 
material. 
5.2  CYCLOPHOSPHAMIDE 
Mechanism of action: a nitrogen mustard derivative, is converted to polyfunctional alkylating 
metabolites by hepatic microsomal enzymes. It interferes with DNA replication and RNA 
transcription, and possesses potent immunosuppressive activity. 
Formulation: The drug is supplied as a lyophilized powder in 100 mg, 200 mg, 500 mg, l g, 
and 2 g vials.  
Preparation/Storage: It is reconstituted to result in a concentration of 20 mg/mL. It is stable 
for 24 hours at room temperature or for 6 days refrigerated (2°-8° C). 
5.3  DOXORUBICIN 
Mechanism of action: An anthracycline antibiotic derived as a fermentation product of 
Streptomyces peucetius (caesius). The drug is tightly bound to DNA, preventing DNA-
directed DNA and RNA synthesis. The drug may also act via a free radical mechanism. It 
appears to be active in all phases of the cell cycle. 
Formulation: The drug is supplied reconstituted in 10, 50 and 200 mg vials. 
Storage: Reconstituted solutions are stable at room temperature for 24 hours and under 
refrigeration for 48 hours. 
Administration: The drug is administered via a freely-flowing intravenous line over 15 
minutes. Care must be taken to avoid extravasation. 
5.4  VINCRISTINE 
Mechanism of action: Vincristine is a member of the vinca alkaloid class of natural product 
anti-tumor agents. It exerts its antineoplastic effects by binding to tubulin, resulting in 
inhibition of microtubule assembly. This, in turn, blocks formation of the mitotic spindle 
resulting in the accumulation of cells in mitosis. 
Formulation: The drug is supplied reconstituted to a concentration of 1 mg/ Ml 
Preparation/Storage: The drug is administered via a freely-flowing intravenous line over 1-2 
minutes, with care taken to avoid extravasation. 
5.5  PREDNISONE 
Mechanism of action:  Prednisone is a synthetic glucocorticoid.  It is often used to enhance 
the effects of other cancer agents when used in combination.  Given in pharmacologic doses, 
prednisone exerts anti-inflammatory and immunosuppressive effects on the blood and 
lymphatic system.  At the cellular level, prednisone appears to halt DNA synthesis by 
mediating the inhibition of glucose transport or phosphorylation.  In consequence, this 
causes a decrease in available intracellular energy and thus, impedes mitotic division. 
Prednisone is rapidly absorbed from the gastrointestinal tract when administered orally and 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 16 of 50 
 
has a short duration (304 hours) of pharmacologic effects. Animal studies demonstrate that it 
is rapidly distributed to muscles, liver, skin, intestines, and kidneys upon ingestion. 
Formulation: Supplied as tablets ranging from 1 to 50mg 
Storage:  Store at controlled room temperature 15º to 30ºC (59º to 86º F). 
5.6  RITUXIMAB(Rituxan®, C2B8) 
Mechanism of action: Rituximab binds to the CD20 antigen expressed on B-cells and causes 
cell death by complement mediated lysis and ADCC. 
Formulation: Rituximab is supplied as 100 mg and 500 mg sterile, preservative-free, single-
use vials. 
Preparation: The appropriate dose is withdrawn and diluted to a final concentration of 1-4 
mg/ml in either 0.9% sodium chloride or 5% dextrose solution. The solution is then stable at 
2° to 8°C for 24 hours and at room temperature for an additional 12 hours. 
Storage: Vials can be stored at 2o to 8oC. They should be protected from sunlight. 
Administration: Rituximab to be given intravenously per institiutional policy.  
Supplier: Genentech, Inc., IDEC Pharmaceuticals Corp. 
 
5.7  CYTARABINE (HIDAC, Cytosine Arabinoside, Cytosar-U®) 
Mechanism of action: Cytarabine is a cell cycle-specific (S phase) antimetabolite that inhibits 
cell development from the G1 to the S phase. 
Formulation: Cytarabine is supplied in a powder for reconstitution at 100 mg, 500 mg, 1 g, 
and 2 g. It is also present as an injection, and solution concentrations are 20 mg/mL (5 mL, 
25 mL, 50 mL) and 100 mg/mL (20 mL). 
Preparation: Cytarabine must be reconstituted from a 100-mg vial with 5 mL bacteriostatic 
water for injection, yielding 20 mg/mL.  
Storage: Cytarabine must be protected from light. Retain in carton until time of use. Store the 
product at controlled room temperature 15° to 30°C (59° to 86°F). 
Administration: May be administered I.M., I.T., or Subcutaneously at a concentration not to 
exceed 100 mg/mL. When administered via I.V. infusion, infuse over 1-3 hours or as a 
continuous infusion. GI effects may be more pronounced with divided I.V. bolus doses than 
with continuous infusion. 
Supplier: UpJohn  
5.8  NEUPOGEN® (Filgrastim, G-CSF) or NEULASTA® (Pegfilgrastim) 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 17 of 50 
 
Mechanism of action: NEUPOGEN® is a human protein, which is involved in the promotion 
of the growth and maturation of granulocytic progenitors and the stimulation of functional 
activity. 
Formulation: Available as a recombinant DNA product supplied as 1 or 2 ml vials containing 
clear colorless sterile protein solution. 
Storage: It can be stored at 2-6°C and is stable for at least 30 months. 
Supplier: Amgen, Inc. 
Mechanism of action: NEULASTA® is a covalent conjugate of filgrastim and 
monomethoxypolyethylene glycol. It stimulates the production, maturation, and activation of 
neutrophils to increase both their migration and cytotoxicity. Pegfilgrastim has reduced renal 
clearance and prolonged persistence in vivo when compared with filgrastim.  
Formulation: Neulasta® is supplied in 0.6 mL prefilled syringes for subcutaneous injection. 
Each syringe contains 6 mg pegfilgrastim (based on protein weight), in a sterile, clear, 
colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), sorbitol (30.0 mg), 
polysorbate 20 (0.02 mg), and sodium (0.02 mg) in water for injection 
Storage: Neulasta® should be stored refrigerated at 2° to 8°C (36° to 46°F); syringes should 
be kept in their carton to protect from light until time of use. Shaking should be avoided. 
Before 
Neulasta® (pegfilgrastim) injection‚ Neulasta® may be allowed to reach room temperature for 
a maximum of 48 hours but should be protected from light. Neulasta® left at room 
temperature for more than 48 hours should be discarded. Freezing should be avoided; 
however, if accidentally 
frozen, Neulasta® should be allowed to thaw in the refrigerator before administration. If 
frozen a second time, Neulasta® should be discarded. It can be stored at 2-6°C and is stable 
for at least 30 months. 
6.0 
CRITERIA FOR SUBJECT ELIGIBILITY 
This study will include previously untreated mantle cell lymphoma patients. 
6.1 
Subject Inclusion Criteria 
 
Previously untreated mantle cell lymphoma patients (at least clinical stage 2) 
 
Histologic diagnosis confirmed by MSKCC pathologist as mantle cell lymphoma.   
 
Presence of evaluable disease  
 
Age ≥18 years KPS ≥ 70%  
 
Adequate organ function:  ANC ≥1500 and platelet count ≥100,000, unless felt to be 
secondary to underlying mantle cell lymphoma  
 
Renal function assessed by calculated creatinine clearance as follows (see Appendix: 
Cockcroft-Gault estimation of CrCl): 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 18 of 50 
 
o Calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula.  See 
section below, “Dosing Regimen”, regarding lenalidomide dose adjustment for 
calculated creatinine clearance  30ml/min and < 60ml/min. 
 
Adequate hepatic function as determined by  
o Total bilirubin <1.5X upper limit of normal (ULN) (unless known Gilbert 
syndrome) 
o AST (SGOT) and ALT (SGPT)  3 x ULN 
 
All study participants must be registered into the mandatory Revlimid REMS® 
program, and be willing and able to comply with the requirements of the REMS® 
program. 
 
Females of reproductive potential must adhere to the scheduled pregnancy testing as 
required in the Revlimid REMS® program.  
 
Each subject must sign an informed consent form indicating that he or she 
understand the purpose of and procedures required for the study and are willing to 
participate.   
 
Short course systemic corticosteroids is permissible for disease control, improvement 
of performance status or non-cancer indication if < 10 days and must be discontinued 
prior to study treatment.   
6.2 
Subject Exclusion Criteria 
 
Known central nervous system (CNS) lymphoma 
 
Uncontrolled or severe cardiovascular disease or left ventricular ejection fraction 
<50% as determined by echocardiogram or MUGA.  
 
Any life-threatening illness, medical condition, or organ system dysfunction which, in 
the investigator’s opinion, could compromise the subject’s safety or put the study 
outcomes at undue risk.  
 
Pregnant or breast-feeding. Pre-menopausal patients must have a negative serum 
HCG within 14 days of enrollment.  
 
Patients using ≥20 mg/day of prednisone (or steroid equivalent dose) for any chronic 
medical condition.  
 
Known seropositive, requiring anti-viral therapy, and with detectable viral load by 
PCR for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C 
virus (HCV). 
 
Known hypersensitivity to thalidomide or lenalidomide  
 
The development of erythema nodosum if characterized by a desquamating rash 
while taking thalidomide or similar drugs. 
 
Patients planned for upfront consolidation with high-dose therapy and autologous 
stem cell transplant.  
7.0 
RECRUITMENT PLAN 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 19 of 50 
 
Patients seen in the inpatient or outpatient setting who meet eligibility criteria will be recruited 
to this study. An attending physician will evaluate all patients. Participation is voluntary. The 
consenting physician will inform patients of their diagnosis, current treatment options, 
including standard treatment, and the risks, benefits and experimental nature of this 
treatment program. All patients will be required to sign a statement of informed consent that 
conforms to FDA and IRB guidelines. 
8.0 
PRETREATMENT EVALUATION 
 
Prior to initiating treatment:  
o Adequate material is required to confirm the diagnosis of mantle cell lymphoma (if 
pathologic material is not available a repeat biopsy is necessary). The 
immunohistochemistry studies may include: CD20, CD3, CD5, cyclin D1, Ki-67, SOX-
11, p53, p27, p16, cyclin D2, or cyclin D3. FISH demonstrating the CCDN1 
translocation [t(11;14)] provides further support of diagnosis, but is not required for 
making the diagnosis.   
o If possible, obtain tissue block or 15-20 unstained slides from initial diagnostic biopsy 
for correlative studies. 
o Baseline tumor biopsy to identify tumor-specific clonotype. The specimen can be from 
lymph node, GI tract, bone marrow, or blood. The ID Test Specimen 
Recommendations are detailed in Appendix 1.   
 
Within 16 weeks: 
o Gastrointestinal evaluation with upper endoscopy and colonoscopy with blind biopsy 
is advisable when clinically indicated and acceptable from a risk-benefit standpoint.. 
This is a recommended, not mandatory, evaluation and should be completed at the 
discretion of the treating physician. 
 
Within 6 weeks prior to initiating treatment:  
o CT scans of chest, abdomen, and pelvis and FDG-PET scan for pretreatment staging 
(can include CT neck if appropriate per physician discretion) 
o Unilateral bone marrow biopsy and aspirate, unless the patient has evidence of 
leukemic phase disease (confirmed presence of circulating mantle cell lymphoma 
cells in the peripheral blood). 
o Electrocardiogram  
o Echocardiogram or MUGA scan  
o Hepatitis B surface antigen and core antibody 
o Hepatitis C antibody 
o HIV 1/2 antibodies 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 20 of 50 
 
 
2 weeks prior to initiating treatment: 
o History and physical including height, weight, and vital signs 
o Karnofsky or Eastern Cooperative Oncology Group (ECOG) performance status 
o Complete blood count with differential 
o Serum lactate dehydrogenase 
o Comprehensive Metabolic Panel 
o Serum pregnancy test in pre-menopausal women 
o Baseline peripheral blood test for potential clone identification and MRD analysis (1 
EDTA tube with 10cc of fresh peripheral blood). See Appendix 1 for detailed 
recommendations for MRD test specimen collection.   
o Research blood tests (2 Cell Preparation Tube (CPT) tubes with 8cc of peripheral 
blood and 1 serum separator tube (SST) with 8.5 cc of peripheral blood) 
9.0 
TREATMENT/INTERVENTION PLAN 
9.1  
INDUCTION: Lenalidomide + R-CHOP CHEMOTHERAPY: 4 cycles every 3 weeks 
± 3 days  
 
Lenalidomide-R-CHOP will be administered every 3 weeks (+/- 3 days) as an outpatient 
per institution policy at the following doses: 
o Rituximab 375 mg/m2 IVPB with premedications Day 1 
o Cyclophosphamide 750 mg/m2 IVPB Day 1 
o Doxorubicin 50 mg/m2 IVP Day 1 
o Vincristine 1.4 mg/m2 IVP (capped at 2 mg) Day 1 
o Prednisone 100 mg PO Daily on Days 1-5 or Days 2-6 
o Lenalidomide 15 mg PO Daily on Days 1-14  
 
Per physician discretion, rituximab can be administered as a “split dose” over days 1 and 2 to 
reduce the likelihood of a rituximab-related injection reaction in patients with leukemic phase 
disease. 
Lenalidomide Dosing: 
Patients with moderate renal insufficiency (creatinine clearance ≥30 mL/min but <60 mL/min) 
will receive a lower dose of lenalidomide of 10 mg PO Daily on Days 1-14.  
At investigator discretion, patients started with a reduced lenalidomide dose due to baseline 
calculated creatinine clearance ≥ 30ml/min but < 60ml/min, may have their lenalidomide dose 
gradually increased in a step-wise manner at the start of Cycle 2 or at the start of subsequent 
treatment cycles, if they tolerated the prior treatment cycle without requiring dose 
modifications, interruptions or delays due to toxicity.  Lenalidomide dose titrations are 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 21 of 50 
 
permitted in 5mg increments on the same dosing schedule up to the maximum allowable 
target dose.   
Dosing will be at approximately the same time each day.  Prescriptions must be filled within 7 
days for females of child bearing potential and 14 days for all other risk categories. 
Swallow lenalidomide capsules whole with water at the same time each day.  Do not break, 
chew or open the capsules.   
If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day.  
If it is missed for the entire day, it should not be made up. 
Patients who take more than the prescribed dose of lenalidomide should be instructed to 
seek emergency medical care if needed and contact study staff immediately. 
 
Supportive care: 
o Premedication will be given per institutional guidelines 
o Anti-emetics will be given per institutional guidelines 
o Aspirin 81 mg PO Days 1-21 (daily throughout every cycle) for venous 
thromboembolism prophylaxis. If aspirin is contraindicated, alternate anticoagulant 
agent for prophylaxis of VTE should be initiated per physician discretion and tailored 
to the patient’s individual risk/benefit profile by taking into account the patient’s 
thrombotic risk, bleeding risk, and other relevant factors. Aspirin can be deferred if the 
patient is already on prophylactic or therapeutic dose anticoagulation.   
o Mandatory growth factor support will be provided after each cycle of Lenalidomide-R-
CHOP with either pegfilgrastim, filgrastim, or alternate growth factor per physician 
discretion.  
 
 
Prophylactic antibiotics (all):  
o Acyclovir 400 mg PO BID or Valacyclovir 500 mg PO QD  
o Sulfamethoxazole/trimethoprim double-strength 1 tab PO three times per week OR 
single-strength 1 tab daily.    
 
Note: Patients allergic or intolerant to sulfa drugs can receive either dapsone 100 mg PO 
daily if not G6PD deficient, atovaquone 750 mg PO BID, or pentamidine 300 mg by nebulizer 
every 4 weeks as an alternative. 
 
 
Dose delays/reductions 
o Patients with absolute neutrophil count < 1000 cells/ul or platelet count < 50,000 cells/ul 
on the scheduled day of treatment may be delayed up to 2 weeks. 
o Patients experiencing ≥ grade 2 neurotoxicity will have their vincristine dose-reduced by 
50%.   
o Any dose reduction that is made will be applied to all subsequent cycles. 
 
Dose Reduction Steps 
 
Table 1: LENALIDOMIDE Dose Reduction Steps 
 
Starting Dose 
15 mg daily on Days 1-
14every 21days 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 22 of 50 
 
Dose Level – 1 
10 mg daily on Days 1-14 every 
21 days 
Dose Level – 2 
5 mg daily on Days 1-14 every 
21 days 
 
* Lenalidomide 5 mg daily on Days 1-14 every 21 days is the minimum lenalidomide dose.  
Lenalidomide will be discontinued in patients who cannot tolerate this dose.  However, 
patients who experience toxicity requiring dose reduction while receiving lenalidomide 5 mg 
daily on Days 1-14 every 21 days may, at the discretion of their physician, have their dose 
held until toxicity resolves and then restart lenalidomide 5 mg daily.  If the same toxicity 
recurs at lenalidomide 5 mg daily, consideration should be given to discontinuing 
lenalidomide. 
 
Instructions for initiation of a New Cycle  
 
A new course of treatment may begin on the scheduled Day 1 of a new cycle if: 
 
 
The ANC is ≥1,000 cells/ul;  
 
The platelet count is ≥ 50,000 cells/ul; 
 
Any drug-related rash or neuropathy that may have occurred has resolved to ≤ grade 1 
severity; 
 
Any other drug-related adverse events that may have occurred have resolved to ≤ grade 2 
severity.  
 
Same day results are not required from the comprehensive metabolic panel (including renal 
function and liver function testing) to assess for non-hematologic laboratory toxicity prior to 
treatment on day 1 of each new cycle. It is acceptable to review the comprehensive 
metabolic panel results that were obtained within 23 days prior to day 1 of each cycle.  
 
If these conditions are not met on Day 1 of a new cycle, the subject will be evaluated within a 
week and a new cycle of treatment will not be initiated until the toxicity has resolved as 
described above. If the cycle is delayed > 4 weeks, then the patient will be removed from 
study.  
 
 
Instructions for dose modifications or interruption during a cycle 
Table 2: Dose Modifications 
NCI CTC Toxicity Grade 
Dose Modification Instructions  
 
Grade 3 or 4 neutropenia 
associated with fever 
(temperature ≥ 38.5º C)  
 
Hold (interrupt) lenalidomide dose. 
 
Follow CBC at least weekly. 
 
If neutropenia has resolved to ≤ grade 2 (ANC ≥ 
1000/mm3) prior to Day 14 of the current cycle, restart 
lenalidomide at next lower dose level and continue 
through the scheduled Day 14 of the current cycle.  
Otherwise, omit for remainder of cycle and reduce the 
dose of lenalidomide by 1 dose level at the start of the 
next cycle.  Omitted doses are not made up 
 
Grade 3 or 4 neutropenia 
without fever 
 
Continue lenalidomide dosing, no interruptions or 
reductions required.  
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 23 of 50 
 
Table 2: Dose Modifications 
NCI CTC Toxicity Grade 
Dose Modification Instructions  
 
Thrombocytopenia ≥Grade 3 
(platelet count < 50,000/mm³) 
 
Continue lenalidomide dosing, no interruptions or 
reductions required. 
 
 
Thrombocytopenia ≥Grade 3 
(platelet count < 50,000/mm³) 
with associated bleeding 
 
Hold (interrupt) lenalidomide dose. 
 
Follow CBC at least weekly. 
 
If thrombocytopenia resolves to ≤ grade 2 (platelet count 
≥ 50,000/mm3) prior to Day 14 of the current cycle, 
restart lenalidomide at next lower dose level and 
continue through the scheduled Day 14 of the current 
cycle.  Otherwise, omit for remainder of cycle and reduce 
the dose of lenalidomide by 1 dose level at the start of 
the next cycle.  Omitted doses are not made up. 
            Non-blistering rash 
 
 
 
 
 
 
 
See Table 3 for management 
 
Desquamating (blistering) 
rash- any Grade  
 
Discontinue lenalidomide.  
Neuropathy 
 
Grade 3 
 
 
 
 
 
 
 
 
Grade 4 
 
 
If Grade 3, hold (interrupt) lenalidomide dose.  Follow at 
least weekly. 
 
If the toxicity resolves to ≤ grade 1 prior to Day 14 of the 
current cycle, restart lenalidomide at next lower dose 
level and continue through the scheduled Day 14 of the 
current cycle.  Otherwise, omit for remainder of cycle 
and reduce the dose of lenalidomide by 1 dose level at 
the start of the next cycle.  Omitted doses are not made 
up. 
 
 
If Grade 4, discontinue lenalidomide.  Remove patient 
from study. 
Venous 
thrombosis/embolism 
≥ Grade 3 
 
Hold (interrupt) lenalidomide and start therapeutic 
anticoagulation, if appropriate. 
 
Restart lenalidomide at investigator’s discretion 
(maintain dose level). 
Hyperthyroidism or 
hypothyroidism 
 
Omit lenalidomide for remainder of cycle, evaluate 
etiology, and initiate appropriate therapy.  
 
If toxicity has resolved to ≤ grade 2 severity, restart for 
the next cycle and reduce the dose of lenalidomide by 1 
dose level. 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 24 of 50 
 
Table 2: Dose Modifications 
NCI CTC Toxicity Grade 
Dose Modification Instructions  
 
Other non-hematologic 
toxicity ≥ Grade 3 
 
Hold (interrupt) lenalidomide dose.  Follow at least 
weekly. 
 
If the toxicity resolves to ≤ grade 2 prior to Day 14 of the 
current cycle, restart lenalidomide and continue through 
the scheduled Day 14 of the current cycle.  Otherwise, 
omit for remainder of cycle.  Omitted doses are not made 
up.  For toxicity attributed to lenalidomide, reduce the 
lenalidomide dose by 1 dose level when restarting 
lenalidomide. 
 
Table 3: Management of lenalidomide-related rash (non-blistering) 
Grade 
Description 
(CTCAE) 
Lenalidomide management 
Recommended rash 
management 
1 
<10% of BSA 
No action required 
Treat with topical 
corticosteroids and oral 
antihistamines until resolution 
of rash/symptoms 
 
Short course of low-dose 
oral steroid (prednisone 
10mg or equivalent) is 
allowed 
2 
10-30% of BSA Consider interruption (holding) 
lenalidomide 
 
If the rash resolves to ≤ grade 1 
prior to Day 14 of the current 
cycle, restart lenalidomide at 
next lower dose level and 
continue through the scheduled 
Day 14 of the current cycle.  
Otherwise, omit for remainder of 
cycle and reduce the dose of 
lenalidomide by 1 dose level at 
the start of the next cycle.  
Omitted doses are not made up. 
 
Treat with topical 
corticosteroids and oral 
antihistamines until resolution 
of rash/symptoms or ≤grade 1 
 
Short course of low-dose 
oral steroid (prednisone 
10mg or equivalent) is 
allowed 
3 
>30% of BSA 
Hold lenalidomide 
 
If the toxicity resolves to ≤ grade 
1 prior to Day 14 of the current 
cycle, restart lenalidomide at 
next lower dose level and 
continue through the scheduled 
Day 14 of the current cycle.  
Otherwise, omit for remainder of 
cycle and reduce the dose of 
lenalidomide by 1 dose level at 
the start of the next cycle.  
Omitted doses are not made up. 
 
Treat with topical 
corticosteroids and oral 
antihistamines until resolution 
of rash/symptoms or ≤grade 1 
 
Short course of low-dose 
oral steroid (prednisone 
10mg or equivalent) is 
allowed 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 25 of 50 
 
4 
Life 
threatening 
Discontinue lenalidomide.  Remove 
patient from study. 
Medical intervention as 
appropriate 
Abbreviations: BSA = body surface area; CTCAE = Common Terminology Criteria for Adverse Events 
 
Restaging after Lenalidomide-RCHOP cycle 4: 
o Restaging FDG-PET scans 17 to 28 days after day 1 of the 4th cycle of Lenalidomide-
RCHOP. Patients without evidence of progressive disease (Deauville 5) may proceed to 
consolidation with R-HIDAC. 
 
9.2 CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 3 days 
 
R-HIDAC will be administered within 21-28days of completing the last cycle of Lenalidomide-
R-CHOP.   
 
R-HIDAC will be administered once every 3 weeks ± 3 days for 2 cycles. 
 
R- HIDAC will be administered in the following manner: Rituximab 375mg/m2 will be 
administered as an outpatient on day 1, where the patient will be seen by a study 
investigator. Patients will then be admitted for HIDAC on day 2 (+/- 2 days). Patients will be 
allowed admission at Overlook Hospital, a local hospital that is affiliated with Memorial Sloan 
Kettering. All research assessments and tests will be performed at the outpatient visit on day 
1, and there will be no assessments done during their inpatient stay for HIDAC. All follow-up 
notes from the affiliated hospitals will be submitted to our Electronic Medical Records to 
account for any adverse events that may occur while in-patient.  Patient will be discharged at 
the completion of HIDAC administration. 
 
Inpatient HIDAC will be administered as follows: 
o Cytarabine [DOSE] IVPB over 3 hours every 12 hours x 4 doses 
o The DOSE of cytarabine will be determined at the discretion of the treating physician. 
We recommend the cytarabine dose is adjusted based upon age. Suggested guidelines 
are shown in chart below.  
 
Age 
DOSE 
Regimen 
≤70 
2,000 mg/m2 
Every 12 hours X 4 doses 
>70 years 
1,000 mg/m2 
Every 12 hours X 4 doses 
 
Supportive care: 
o Premedications, anti-emetics, and hematopoietic growth factors will be administered per 
institutional guidelines. 
o Patients will continue to receive prophylactic antibiotics as outlined in section 9.1. 
o Patients will receive growth factor support after each cycle with pegfilgrastim, filgrastim, 
or alternate growth factor per physician discretion. After cycle 2, per physician discretion, 
patients can undergo optional stem cell collection. In this case, standard growth factor 
support is not required.   
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 26 of 50 
 
o Steroid eyedrops may be used at the discretion of the investigator. 
 
Dose delays/reductions:  
o Patients with absolute neutrophil count < 1000 cells/ul or platelet count < 50,000 cells/ul 
may be delayed for up to 5 weeks following their last cycle of chemotherapy. 
o Patients with serum creatinine ≥1.5 mg/dL or creatinine clearance ≤ 50 ml/hr on the 
scheduled day of HIDAC will be delayed for up to two weeks. 
 
Optional stem cell collection after cycle 2 of HIDAC: 
o At the treating physician’s discretion, patients can undergo stem cell collection after 
cycle 2 of R-HIDAC for future use. Stem cell mobilization would be carried out per 
physician discretion.   
Restaging after R-HIDAC Cycle 2: 
Restaging FDG-PET scans should be completed prior to cycle 1 of rituximab and 
lenalidomide maintenance.. Patients without evidence of progressive disease (Deauville 5) 
may proceed to lenalidomide-rituximab maintenance. 
 
9.3 MAINTENANCE: Lenalidomide + Rituximab for 6 months  
 
Lenalidomide and rituximab maintenance will begin within 3-5 weeks after day 1 of the 
2nd cycle of RHIDAC. 
 
Lenalidomide will be administered on days 1-21 of a 28-day cycle for a total of 6 cycles 
(total 6 months) at the following dose:  
o Lenalidomide 15 mg PO Daily on Days 1-21  
 
Patients with moderate renal insufficiency (creatinine clearance ≥30 mL/min but <60 mL/min) 
will receive a lower dose of lenalidomide of 10 mg PO Daily on Days 1-21.  
 
Rituximab will be administered on day 1 every 8 weeks for (+/- 3 days) for a total of 3 
cycles (total 6 months) at the following dose: 
 
o Rituximab 375 mg/m2 IVPB Day 1 
 
Lenalidomide and rituximab maintenance is continued for 6 months or until disease 
progression, unacceptable toxicity, or voluntary withdrawal.  
 
Supportive care: 
o Premedication will be given per institutional guidelines 
o Anti-emetics will be given per institutional guidelines 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 27 of 50 
 
o Aspirin 81 mg PO Daily throughout 6 months of lenalidomide maintenance therapy for 
venous thromboembolism prophylaxis. If aspirin is contraindicated, alternate 
anticoagulant agent for prophylaxis of VTE should be initiated per physician discretion 
and tailored to the patient’s individual risk/benefit profile by taking into account the 
patient’s thrombotic risk, bleeding risk, and other relevant factors. Aspirin can be 
deferred if the patient is already on prophylactic or therapeutic dose anticoagulation.   
 
 
Prophylactic antibiotics:  
o Acyclovir 400 mg PO BID  
 
 
Dose delays/reductions 
 
The lenalidomide starting dose will be based on baseline calculated creatinine clearance as 
follows: 
Lenalidomide Starting Dose Based on Renal Function at Study Entry 
Baseline Calculated 
Creatinine Clearance 
(by Cockcroft-Gault) 
Starting Lenalidomide Dose 
 60 ml/min 
15 mg daily on Days 1 - 21 of each 28-day 
cycle  
 30 and < 60 ml/min 
10mg daily on Days 1 - 21 of each 28-day 
cycle 
 
At investigator discretion, patients started with a reduced lenalidomide dose due to baseline 
calculated creatinine clearance ≥ 30ml/min but < 60ml/min, may have their lenalidomide dose 
gradually increased in a step-wise manner at the start of Cycle 2 or at the start of subsequent 
treatment cycles, if they tolerated the prior treatment cycle without requiring dose 
modifications, interruptions or delays due to toxicity.  Lenalidomide dose titrations are 
permitted in 5mg increments on the same dosing schedule up to the maximum allowable 
target dose.   
 
The lenalidomide dose may only be increased once every 28 days (or less frequently), and 
may only be increased if the prior treatment cycle was completed without requiring dose 
modifications, interruptions or delays due to toxicity.   
 
Dosing will be at approximately the same time each day.  Prescriptions must be filled within 7 
days for females of child bearing potential and 14 days for all other risk categories. 
 
Swallow lenalidomide capsules whole with water at the same time each day.  Do not break, 
chew or open the capsules.  If a dose of lenalidomide is missed, it should be taken as soon 
as possible on the same day.  If it is missed for the entire day, it should not be made up. 
Patients who take more than the prescribed dose of lenalidomide should be instructed to 
seek emergency medical care if needed and contact study staff immediately. 
 
Dose Reduction Steps 
 
Table 1: LENALIDOMIDE Dose Reduction Steps 
 
Starting Dose 
15 mg daily on Days 1-21 
every 28 days 
 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 28 of 50 
 
Dose Level – 1 
10 mg daily on Days 1-21 every 
28 days 
Dose Level – 2 
5 mg daily on Days 1-21 every 
28 days 
 
* Lenalidomide 5 mg daily on Days 1-21 every 28 days is the minimum lenalidomide dose.  
Lenalidomide will be discontinued in patients who cannot tolerate this dose.  However, 
patients who experience toxicity requiring dose reduction while receiving lenalidomide 5 mg 
daily on Days 1-21 every 28 days may, at the discretion of their physician, have their dose 
held until toxicity resolves and then restart lenalidomide 5 mg daily on Days 1-21 every 28 
days.  If the same toxicity recurs at lenalidomide 5 mg daily on Days 1-21 every 28 days, 
consideration should be given to discontinuing lenalidomide. 
 
Instructions for initiation of a New Cycle  
A new course of treatment may begin on the scheduled Day 1 of a new cycle if: 
 
 
The ANC is ≥1,000 cells/ul;  
 
The platelet count is ≥ 50,000 cells/ul; 
 
Any drug-related rash or neuropathy that may have occurred has resolved to ≤ grade 1 
severity; 
 
Any other drug-related adverse events that may have occurred have resolved to ≤ grade 2 
severity.  
 
If these conditions are not met on Day 1 of a new cycle, the subject will be evaluated within a 
week and a new cycle of treatment will not be initiated until the toxicity has resolved as 
described above.  
 
 
 
 
 
Instructions for dose modifications or interruption during a cycle 
Table 2: Dose Modifications 
NCI CTC Toxicity Grade 
Dose Modification Instructions  
 
Grade 3 neutropenia 
associated with fever 
(temperature ≥ 38.5º C) or 
Grade 4 neutropenia 
 
Hold (interrupt) lenalidomide dose. 
 
Follow CBC weekly. 
 
If neutropenia has resolved to ≤ grade 2 prior to Day 
21 of the current cycle, restart lenalidomide at next 
lower dose level and continue through the 
scheduled Day 21 of the current cycle.  Otherwise, 
omit for remainder of cycle and reduce the dose of 
lenalidomide by 1 dose level at the start of the next 
cycle.  Omitted doses are not made up.   
 
If neutropenia is the only toxicity for which a dose 
reduction is required, G-CSF may be used and the 
lenalidomide dose maintained. 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 29 of 50 
 
Table 2: Dose Modifications 
NCI CTC Toxicity Grade 
Dose Modification Instructions  
 
Thrombocytopenia ≥Grade 3 
(platelet count < 
50,000/mm³) 
 
Hold (interrupt) lenalidomide dose. 
 
Follow CBC weekly. 
 
If thrombocytopenia resolves to ≤ grade 2 prior to 
Day 21 of the current cycle, restart lenalidomide at 
next lower dose level and continue through the 
scheduled Day 21 of the current cycle.  Otherwise, 
omit for remainder of cycle and reduce the dose of 
lenalidomide by 1 dose level at the start of the next 
cycle.  Omitted doses are not made up. 
            Non-blistering rash 
 
 
 
 
See Table 3 for management 
Desquamating (blistering) 
rash- any Grade  
 
Discontinue lenalidomide.  
Neuropathy 
 
Grade 3 
 
 
 
 
 
 
 
 
Grade 4 
 
 
If Grade 3, hold (interrupt) lenalidomide dose.  
Follow at least weekly. 
 
If the toxicity resolves to ≤ grade 1 prior to Day 21 of 
the current cycle, restart lenalidomide at next lower 
dose level and continue through the scheduled Day 
21 of the current cycle.  Otherwise, omit for 
remainder of cycle and reduce the dose of 
lenalidomide by 1 dose level at the start of the next 
cycle.  Omitted doses are not made up. 
 
 
If Grade 4, discontinue lenalidomide.  Remove 
patient from study. 
Venous 
thrombosis/embolism 
≥ Grade 3 
 
Hold (interrupt) lenalidomide and start therapeutic 
anticoagulation, if appropriate. 
 
Restart lenalidomide at investigator’s discretion 
(maintain dose level). 
Hyperthyroidism or 
hypothyroidism 
 
Omit lenalidomide for remainder of cycle, evaluate 
etiology, and initiate appropriate therapy.  
 
If toxicity has resolved to ≤ grade 2 severity, restart 
for the next cycle and reduce the dose of 
lenalidomide by 1 dose level. 
Other non-hematologic 
toxicity ≥ Grade 3 
 
Hold (interrupt) lenalidomide dose.  Follow at least 
weekly. 
 
If the toxicity resolves to ≤ grade 2 prior to Day 21 of 
the current cycle, restart lenalidomide and continue 
through the scheduled Day 21 of the current cycle.  
Otherwise, omit for remainder of cycle.  Omitted 
doses are not made up.   
 
For toxicity attributed to lenalidomide, reduce the 
lenalidomide dose by 1 dose level when restarting 
lenalidomide. 
 
 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 30 of 50 
 
Table 3: Management of lenalidomide-related rash (non-blistering) 
Grade 
Description 
(CTCAE) 
Lenalidomide management 
Recommended rash 
management 
1 
<10% of BSA 
No action required 
Treat with topical 
corticosteroids and oral 
antihistamines until 
resolution of 
rash/symptoms 
 
Short course of low-
dose oral steroid 
(prednisone 10mg 
or equivalent) is 
allowed 
2 
10-30% of BSA Consider interruption (holding) 
lenalidomide 
 
If the rash resolves to ≤ grade 1 
prior to Day 14 of the current 
cycle, restart lenalidomide at 
next lower dose level and 
continue through the scheduled 
Day 14 of the current cycle.  
Otherwise, omit for remainder of 
cycle and reduce the dose of 
lenalidomide by 1 dose level at 
the start of the next cycle.  
Omitted doses are not made up. 
 
Treat with topical 
corticosteroids and oral 
antihistamines until 
resolution of 
rash/symptoms or ≤grade 
1 
 
Short course of low-
dose oral steroid 
(prednisone 10mg 
or equivalent) is 
allowed 
3 
>30% of BSA 
Hold lenalidomide 
 
If the toxicity resolves to ≤ grade 
1 prior to Day 14 of the current 
cycle, restart lenalidomide at 
next lower dose level and 
continue through the scheduled 
Day 14 of the current cycle.  
Otherwise, omit for remainder of 
cycle and reduce the dose of 
lenalidomide by 1 dose level at 
the start of the next cycle.  
Omitted doses are not made up. 
 
Treat with topical 
corticosteroids and oral 
antihistamines until 
resolution of 
rash/symptoms or ≤grade 
1 
 
Short course of low-
dose oral steroid 
(prednisone 10mg 
or equivalent) is 
allowed 
4 
Life 
threatening 
Discontinue lenalidomide.  Remove 
patient from study. 
Medical intervention as 
appropriate 
Abbreviations: BSA = body surface area; CTCAE = Common Terminology Criteria for Adverse Events 
 
 
Prior to administration of treatment during any phase (RCHOP, RHIDAC, or R-Lenalidomide), a 
complete blood count (CBC) obtained within 3 days of day 1 is required. However, a comprehensive 
metabolic panel obtained within 30 days of day 1 of treatment can be used to determine dosing, 
including delays and reductions.  
 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 31 of 50 
 
10.0 EVALUATION DURING TREATMENT/INTERVENTION 
 
Tests to be performed within 3 days of day 1 of each cycle of lenalidomide and 
RCHOP: 
 
History and physical exam (MD, PA, or NP evaluation) 
 
KPS or ECOG performance Status 
 
Adverse event and toxiticy review 
 
CBC 
 
Comprehensive metabolic panel (includes: Electrolytes [Na, K, Cl, CO2], BUN, 
Creatinine, bilirubin, total protein, albumin, AST, ALT, alkaline phosphatase) 
 
 
Tests to be performed after completion of 4 cycles of lenalidomide and RCHOP: 
 
Restaging FDG-PET scans 17 to 28 days after 4th cycle of Lenalidomide-RCHOP. 
 
Peripheral blood test for MRD analysis (1 EDTA tube with 10cc of fresh peripheral 
blood). See Appendix 1 for detailed recommendations for MRD test specimen 
collection. To be performed 17 to 28 days after 4th cycle of Lenalidomide-RCHOP. 
 
Research blood tests (2 Cell Preparation Tube (CPT) tubes with 8cc of peripheral 
blood and 1 serum separator tube (SST) with 8.5 cc of peripheral blood). To be 
performed 17 to 28 days after 4th cycle of Lenalidomide-RCHOP. 
 
 
Tests to be performed within 3 days of each cycle of R-HIDAC: 
 
History and physical exam (MD, PA, or NP evaluation) 
 
Adverse event and toxicity review 
 
CBC 
 
Comprehensive metabolic panel ((includes: Electrolytes [Na, K, Cl, CO2], BUN, 
Creatinine, bilirubin, total protein, albumin, AST, ALT, alkaline phosphatase) 
 
 
Tests to be performed after completion of 2 cycles of R-HIDAC: 
 
Restaging FDG-PET scans 17 to 35 days after cycle 2 of R-HIDAC. 
 
Peripheral blood test for MRD analysis (1 EDTA tube with 10cc of fresh peripheral 
blood). See Appendix 1 for detailed recommendations for MRD test specimen 
collection. To be performed 17 to 35 days after cycle 2 of R-HIDAC. 
 
Research blood tests (2 Cell Preparation Tube (CPT) tubes with 8cc of peripheral 
blood and 1 serum separator tube (SST) with 8.5 cc of peripheral blood). To be 
performed 17 to 35 days after cycle 2 of R-HIDAC. 
 
  
 
Tests to be performed within 3 days of each 28-cycle of lenalidomide and rituximab 
maintenance 
 
History and physical exam (MD, PA, or NP evaluation) 
 
Adverse event and toxicity review 
 
CBC 
 
Comprehensive metabolic panel ((includes: Electrolytes [Na, K, Cl, CO2], BUN, 
Creatinine, bilirubin, total protein, albumin, AST, ALT, alkaline phosphatase) 
 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 32 of 50 
 
 
Tests to be performed 6 weeks (+/- 2 weeks) after completion of maintenance 
lenalidomide and rituximab: 
 
History and physical exam (MD, PA, or NP evaluation) 
 
Adverse event and toxicity review 
 
CBC 
 
Comprehensive metabolic panel (includes: Electrolytes [Na, K, Cl, CO2], BUN, 
Creatinine, bilirubin, total protein, albumin, AST, ALT, alkaline phosphatase) 
 
LDH 
 
FDG-PET scan 
 
CT of chest, abdomen, and pelvisUnilateral bone marrow biopsy and aspirate (if 
previously involved) 
 
Upper and lower GI tract evaluation (if previously involved) 
 
Peripheral blood test for MRD analysis (1 EDTA tube with 10cc of fresh peripheral 
blood). See Appendix 1 for detailed recommendations for MRD test specimen 
collection. 
 
Research blood tests (2 Cell Preparation Tube (CPT) tubes with 8cc of peripheral 
blood and 1 serum separator tube (SST) with 8.5 cc of peripheral blood) 
 
 
Tests to be performed 6 months (+/- 1 month) after completion of maintenance 
lenalidomide and rituximab: 
 
Peripheral blood test for MRD analysis (1 EDTA tube with 10cc of fresh peripheral 
blood). See Appendix 1 for detailed recommendations for MRD test specimen 
collection. 
 
Research blood tests (2 Cell Preparation Tube (CPT) tubes with 8cc of peripheral 
blood and 1 serum separator tube (SST) with 8.5 cc of peripheral blood) 
 
 
Long Term Follow Up 
 
Clinical evaluation (including H&P, CBC, CMP, and LDH) every 3 months (+/- 1 
month) for three years after end-of-treatment evaluation..  
 
CT chest, abdomen, pelvis every 6 months (+/- 1 month) for three years after end-
of-treatment evaluation. 
After 3 years post-long term follow up, patients will be seen at the treating physician’s discretion. 
 
 
Interventions 
  
Procedures 
Screen 
Treatment 
EOT 
Induction 
Maintenance 
 
Len-RCHOP 
(outpatient) 
Restage 
17-28 
days post 
C4D1 
R-HiDAC 
(inpatient) 
Within 3-4 
w eeks of 
completion of 
C4D1 
Restage 
17-35 
days post 
C2D1 
Len-R 
(3-5 w eeks of induction 
C2D1) 
C1 
C2 
C3 
C4 
 
C1 
C2 
 
C
1 
C
2  
C
3 
C
4 
C
5 
C
6 
6 wks 
post-tx 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 33 of 50 
 
(+/- 2 
weeks) 
History and 
Physical 
X 
X 
X 
X 
X 
 
X 
X 
 
X 
X X X X X 
X 
Performance 
Status 
X 
X 
X 
X 
X 
 
X 
X 
 
X 
X X X X X 
 
Adverse Events 
 
X 
X 
X 
X 
 
X 
X 
 
X 
X X X X X 
X 
Toxicity Review 
 
X 
X 
X 
X 
 
X 
X 
 
X 
X X X X X 
X 
CBC 
X 
X 
X 
X 
X 
 
X 
X 
 
X 
X X X X X 
X 
Comprehensive 
Metabolic Panel* 
X 
X 
X 
X 
X 
 
X 
X 
 
X 
X X X X X 
X 
Lactate 
dehydrogenase 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Serum β-HCG** 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hep B, C, HIV 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tumor specimen 
for tumor-specific 
clonotype analysis  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MRD blood test 
X 
 
 
 
 
X 
 
 
X 
 
 
 
 
 
 
X*** 
Research blood 
test 
X 
 
 
 
 
X 
 
 
X 
 
 
 
 
 
 
X*** 
GI tract evaluation 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X**** 
BM Bx 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X**** 
FDG-PET/CT  
X 
 
 
 
 
X 
 
 
X 
 
 
 
 
 
 
X 
CT CAP 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
EKG 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Echo or MUGA 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Includes: Electrolytes (Na, K, Cl, CO2), BUN, Creatinine, bilirubin, total protein, albumin, 
AST, ALT, alkaline phosphatase   
 
**premenopausal females 
 
***MRD and research blood test also performed 6 months after conclusion of Len-
Maintenance therapy  
 
****If previously involved at baseline 
 
 
 
11.0 TOXICITIES/SIDE EFFECTS 
Doxorubicin:  
Nausea, vomiting, itching, hives or red rash at the injection site. Urine can be pink or red in 
color for as long as 48 hours after the treatment. Alopecia, stomatitis, and reversible 
myelosuppression can occur. Extravasation may occur if leakage around the intravenous site 
occurs.  Cardiomyopathy has been reported with this compound, usually in patients who 
have received total doses in excess of 500 mg/m2. 
Cyclophosphamide: 
Nausea, vomiting, anorexia, edema, cardiomyopathy, skin rash, alopecia, reversible 
myelosuppression, hemolytic anemia, possible sterility, hemorrhagic cystitis, and syndrome 
of inappropriate antidiuretic hormone production. 
Vincristine: 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 34 of 50 
 
Peripheral neuropathy, constipation, alopecia, metallic taste in the mouth, mild nausea, 
paraesthesia and paresis. Extravasation may result in soft tissue necrosis 
Prednisone: 
Prednisone exerts numerous effects on the body: euphoria, mood swings, fluid retention, 
adrenocortical insufficiency, muscle pain or weakness, muscle wasting, increased 
susceptibility to infections, hypokalemia, hypercorticism, amenorrhea, decreased glucose 
tolerance, hyperglycemia, nausea, vomiting, anorexia, increased appetite, weight gain, 
gastric ulceration, ulcerative esophagitis, insomnia, headache, restlessness, increased motor 
activity, impaired wound healing, skin atrophy and thinning, acne, and increased sweating. 
Lenalidomide:  
Adverse Events 
Most frequently reported adverse events reported during clinical studies with lenalidomide in 
oncologic and non-oncologic indications, regardless of presumed relationship to study 
medication include: anemia, neutropenia, thrombocytopenia and pancytopenia, abdominal 
pain, nausea, vomiting and diarrhea, dehydration, rash, itching, infections, sepsis, pneumonia, 
UTI, Upper respiratory infection, atrial fibrillation, congestive heart failure, myocardial 
infarction, chest pain, weakness, hypotension, hypercalcemia, hyperglycemia, back pain, bone 
pain, generalized pain, dizziness, mental status changes, syncope, renal failure, dyspnea, 
pleural effusion, pulmonary embolism, deep vein thrombosis, CVA, convulsions, dizziness, 
spinal cord compression, syncope, disease progression, death not specified and fractures. 
The following events have been reported during the use of lenalidomide in clinical studies and 
in the post-marketing setting: 
The rare adverse event of angioedema and serious skin reactions including Stevens-Johnson 
syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported.  These events have 
the potential to result in death.  Medical journals have reported patients with allergic skin 
reaction with thalidomide who also developed the same type of reaction with lenalidomide. The 
rare adverse event of rhabdomyolysis has been observed with lenalidomide.   
Tumor lysis syndrome and tumor flare reaction have commonly been observed in patients with 
Chronic Lymphocytic Leukemia (CLL), and uncommonly in patients with other lymphomas, 
who were treated with lenalidomide.  Fatal instances of TLS have been reported during 
treatment with lenalidomide.  There have been rare reports of TLS in patients with multiple 
myeloma treated with lenalidomide, and no reports in patients with myelodysplastic syndrome 
treated with lenalidomide.   
Second New Cancers 
According to researchers, patients with cancer have a higher risk of developing a second new 
cancer when compared to people without cancer. In clinical studies of newly diagnosed 
multiple myeloma, a higher number of second cancers were reported in patients treated with 
lenalidomide as induction therapy (treatment for several cycles to reduce number of cancer 
cells) and/or bone marrow transplant  followed by lenalidomide  for a long period of time 
compared to patients treated with induction therapy and/or bone marrow transplant then 
placebo (a capsule containing no lenalidomide). Patients should make their doctors aware of 
their medical history and any concerns they may have regarding their own increased risk of 
other cancers.  
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 35 of 50 
 
Complete and updated adverse events are available in the Investigational Drug Brochure and 
the IND Safety Letters. 
Other Risks  
Patients should be instructed that if any physician other than the study doctor prescribes 
medication for another condition, or patients start to take any over-the-counter medications or 
vitamins, they must inform the study staff. This is important because the interaction of some 
medications may cause serious side effects.  
o Patients taking lenalidomide and dexamethasone for multiple myeloma 
should be careful taking drugs that may increase chance of having blood 
clots.  
o Cases of transient liver laboratory abnormalities were reported in patients 
treated with lenalidomide.   
o Lenalidomide has been shown to increase the level of digoxin in the blood 
in some patients. 
 
Risks Associated with Pregnancy 
Pregnancy Risk: 
Lenalidomide is related to thalidomide.  Thalidomide is known to cause severe life-threatening 
human birth defects.  Findings from a monkey study indicate that lenalidomide caused birth 
defects in the offspring of female monkeys who received the drug during pregnancy.  If 
lenalidomide is taken during pregnancy, it may cause birth defects or death to any unborn 
baby.  Females must not become pregnant while taking lenalidomide. Patients with multiple 
myeloma who take lenalidomide and dexamethasone have a greater chance of having blood 
clots.  Because of this, it is recommended patients not take birth control pills or hormone 
replacement therapy before discussing with the investigator and considering the risks and 
benefits of these choices.     
When taking lenalidomide, the drug is present in semen of healthy men at very low levels for 
three days after stopping the drug.  For patients who may not break down the drug normally, 
such as patients who do not have normal kidney function, lenalidomide may be present for 
more than three days.  To be safe, all male patients should use condoms when engaging in 
sexual intercourse while taking lenalidomide, when temporarily stopping lenalidomide, and for 
28 days after permanently stopping lenalidomide treatment if their partner is either pregnant or 
able to have children.   
Patients should not donate blood during treatment therapy or for 28 days following 
discontinuation of lenalidomide. 
 
Reproductive risks:  
Patients should not become pregnant or father a baby while on this study because the drugs 
in this study can affect an unborn baby. A woman should NOT CONCEIVE A BABY while she 
or her partner is receiving lenalidomide.  A man should NOT DONATE SPERM OR 
IMPREGNATE HIS PARTNER while he is on lenalidomide.   
Women should not breastfeed a baby while on this study. It is important that the patient 
understand that they will need to use birth control while on this study.   A list of acceptable 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 36 of 50 
 
forms of birth control methods to use and how long to use them is listed below.  Pregnancy 
testing will be required as per Table 7.   
 
 
Pregnancy Risk – Females: 
If a patient is a female of childbearing potential*, she will be required to have two negative 
pregnancy tests: the first test within 10-14 days before lenalidomide is prescribed and the 
second test within 24 hours before lenalidomide is prescribed.  
 
 
 
 
* For the purposes of this study, a female of childbearing potential is a 
sexually mature female who: 1) has not undergone a hysterectomy (the 
surgical removal of the uterus) or bilateral oophorectomy (the surgical 
removal of both ovaries) or 2) has not been naturally postmenopausal 
for at least 24 consecutive months (i.e., has had menses at any time 
during the preceding 24 consecutive months). 
The female patient will be required to use TWO reliable forms of birth control, one highly 
effective method and one additional effective method at the same time or practice complete 
abstinence from heterosexual intercourse during the following time periods related to this 
study: 1) for at least 28 days before starting lenalidomide; 2) throughout lenalidomide therapy, 
including interruptions in therapy; and 3) for at least 28 days after discontinuation of 
lenalidomide.  The following are the acceptable birth control methods:  
Highly Effective Method: 
 
Intrauterine device (IUD) 
 
Hormonal (birth control pills, injections, implants) 
 
Tubal ligation  
Male partner’s vasectomyAdditional Effective Methods: 
 
Latex condom 
 
Diaphragm 
 
Cervical cap 
A female patient must not breastfeed a baby while participating in this study and for at least 28 
days after the discontinuation of lenalidomide.  
Females of childbearing potential with regular or no menstrual cycles must agree to have 
pregnancy tests weekly for the first 28 days and then every 28 days while taking lenalidomide, 
at the time lenalidomide is discontinued, and at day 28 following discontinuation of 
lenalidomide.  If menstrual cycles are irregular, the pregnancy testing must occur weekly for 
the first 28 days and then every 14 days while taking lenalidomide, at discontinuation of 
lenalidomide, and at days 14 and 28 following discontinuation of lenalidomide.   
If the patient has any reason to suspect that they are pregnant, the patient must IMMEDIATELY 
stop taking lenalidomide and contact the physician investigator.   
All Patients: 
Patients must NEVER share lenalidomide with someone else. The patient must receive 
counseling and complete phone surveys as required by the RevAssist® program. 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 37 of 50 
 
The patient should be instructed to swallow lenalidomide capsules whole with water at the 
same time each day.  They should not break, chew or open the capsules.   
If the patient misses a dose of lenalidomide, they should take it as soon as they remember on 
the same day.   
If they miss taking the dose for the entire day, they should take the regular dose the next 
scheduled day (they should NOT take a double regular dose to make up for the missed dose).   
If they take more than the prescribed dose of lenalidomide they should seek emergency 
medical care if needed and contact the study staff immediately. 
Females of childbearing potential that might be caring for you should not touch the 
lenalidomide capsules or bottles unless they are wearing gloves. 
Any unused Revlimid® (lenalidomide) should be returned as instructed through the 
RevAssist® program. 
 
Rituximab: 
Common: Fever, chills, fatigue, headache; less common: nausea, vomiting, rhinitis, pruritus, 
hypotension; rare: neutropenia, thrombocytopenia, asthenia, arrhythmia, tumor lysis 
syndrome, shock, angioedema, acute respiratory distress, arthritis, vasculitis, lupus-like 
syndrome, pleuritis, bronchiolitis obliterans, uveitis, optic neuritis, and skin reactions such as 
toxic epidermal necrolysis and pemphigus. 
Hematologic Events: In clinical trials, Grade 3 and 4 cytopenias were reported in 48% of 
patients treated with RITUXIMAB; these include: lymphopenia (40%), neutropenia (6%), 
leukopenia (4%), anemia (3%), and thrombocytopenia (2%).  The median duration of 
lymphopenia was 14 days (range, 1 to 588 days) and of neutropenia was 13 days (range, 2 
to 116 days).  A single  
occurrence of transient aplastic anemia (pure red cell aplasia) and two occurrences of 
hemolytic anemia following RITUXIMAB therapy were reported. In addition, there have been 
a limited number of postmarketing reports of prolonged pancytopenia, marrow hypoplasia, 
and late onset neutropenia (defined as occurring 40 days after the last dose of RITUXIMAB) 
in patients with hematologic malignancies.  In reported cases of late onset neutropenia (NCI-
CTC Grade 3 and 4), the median duration of neutropenia was 10 days (range 3 to 148 days).  
Documented resolution of the neutropenia was described in approximately one-half of the 
reported cases; of those with documented recovery, approximately half received growth 
factor support.  In the remaining cases, information on resolution was not provided.  More 
than half of the reported cases of delayed onset neutropenia occurred in patients who had 
undergone prior autologous bone marrow transplantation.  In an adequately designed, 
controlled, clinical trial, the reported incidence of NCI-CTC, Grade 3 and 4 neutropenia was 
higher in patients receiving RITUXIMAB in combination with fludarabine as compared to 
those receiving fludarabine alone (76% [39/51] vs. 39% [21/53]). Hepatitis B virus (HBV) 
reactivation with fulminant hepatitis, hepatic failure, and death has been reported in some 
patients with hematologic malignancies treated with rituximab. The majority of patients 
received rituximab in combination with chemotherapy.  The median time to the diagnosis of 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 38 of 50 
 
hepatitis was approximately 4 months after the initiation of rituximab and approximately one 
month after the last dose. Progressive Multifocal Leukoencephalopathy (PML) associated 
with JC virus infection has been reported in patients treated with rituximab with hematologic 
malignancies or with systemic lupus erythematosus (SLE).  PML needs to be considered in 
any patient presenting with new onset neurologic manifestations including confusion, 
dizziness or loss of balance, difficulty talking or walking, and visual changes. 
Cytarabine : 
Cytarabine syndrome, characterized by fever, myalgia, bone pain, chest pain, maculopapular 
rash, conjunctivitis, and malaise. May occur 6-12 hours following administration; may be 
managed with corticosteroids. Myelosuppression (Potent myelosuppressive agent; use with 
caution in patients with prior bone marrow suppression), pancreatitis, tumor lysis syndrome, 
Hepatic impairment: Use with caution in patients with hepatic impairment; may be at higher 
risk for CNS toxicities and dosage adjustments may be required. Can cause renal 
impairment and must be used with caution in patients with impaired renal function. Can 
cause CNS toxicities and dosage adjustments may be required. May also lead to 
pancreatitis: There have been reports of acute pancreatitis in patients receiving continuous 
infusion and in patients previously treated with L-asparaginase. Tumor lysis syndrome has 
been described as well. With high dose therapy, tumor lysis syndrome and subsequent 
hyperuricemia may occur; consider allopurinol and hydrate accordingly. 
Neupogen or Neulasta:   
Bone pain, exacerbation of preexisting autoimmune disorders, transient and reversible 
changes in alkaline phosphatase, uric acid and LDH, splenic rupture. 
11. 1 ADVERSE EVENTS 
Definition:  
An adverse event (AE) is any untoward medical occurrence in a subject participating in an 
investigational trial or protocol regardless of causality assessment. An adverse event can be 
an unfavorable and unintended sign (including an abnormal laboratory finding), symptom, 
syndrome or disease associated with or occurring during the use of an investigational 
product whether or not considered related to the investigational product.  
 
Toxicities will be graded on a scale of 0-5 as described by the NCI- Common Terminology for 
Adverse Events (CTCAE), version 4.0. Only grade 3-5 laboratory toxicities will be reported and 
attributed with regard to relationship to the investigational treatment. 
 
12.0 CRITERIA FOR THERAPEUTIC RESPONSE/OUTCOME ASSESSMENT 
Criteria for interim FDG-PET/CT assessment 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 39 of 50 
 
A five-point scale for visually assessing response on the interim and end-of-treatment FDG-
PET/CT scans, referred to as the “Deauville criteria”, was developed by international experts 
in the field at the First International Workshop on interim-PET in Lymphoma in Deauville in 
2009.42 The 5-point scale is displayed in the following table.  
Score 
FDG-PET/CT scan result 
1 
No residual uptake 
2 
Uptake ≤ mediastinum 
3 
Uptake > mediastinum but ≤ liver 
4 
Uptake moderately > liver 
5 
Markedly increased uptake at any site or 
progression 
 
A positive or abnormal interim FDG-PET/CT scan will be defined as a score of 4 or 5. All 
scores (1 through 5) will be recorded for each FDG-PET/CT scan and scans will be reviewed 
by Dr. Schöder. 
End of treatment FDG-PET/CT assessment 
The updated response criteria entitled “The Lugano Classification” system will be applied to 
define end-of-treatment complete response, partial response, and progression of disease in 
this study.38 The definitions are detailed in the table below: 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 40 of 50 
 
 
 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 41 of 50 
 
 
Progression free survival (PFS) will be calculated from the time of initiation of therapy.  
 
13.0 
CRITERIA FOR REMOVAL FROM STUDY 
Patients will be followed on active follow up for three years after completion of therapy. After the 
active followup period, survival, relapse, and new anti-lymphoma therapy information will be 
collected via telephone calls, patient medical records, and/or clinic visits approximately every 6 
months until death, loss to follow up or consent withdrawal, whichever comes first. 
The following patients will be removed from study:  
• Patients who have progression of disease while on treatment. These patients may be 
offered alternate treatments.  
• Patients who develop unacceptable toxicity.  
• Patients who request that they be removed from study. This will not compromise the care 
they receive at this institution.  
• Patients who are non-compliant with treatment or follow-up.  
 
 
 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 42 of 50 
 
14.0 
BIOSTATISTICS 
Primary Objective: The primary efficacy endpoint of this study is to determine the 3-year 
progression-free survival (PFS) for patients treated with induction chemotherapy consisting 
of lenalidomide with RCHOP and rituximab and high-dose cytarabine followed by 
maintenance therapy with rituximab and lenalidomide. The defining interval for PFS starts at 
enrollment date, and progression of disease or death from any cause will be counted as 
failures. Our past experience suggests that very few patients who have completed the 
induction chemotherapy will be lost to follow-up or withdraw from the study by the end of the 
third year (about 5%). If such rare situations occur, however, they will also be counted as 
failures as well in this study. For this cohort of patients, we will set acceptable 3-yr PFS as 
75% or higher, and unacceptable rate as 60% or lower.  
To this end we will employ a one-stage design. Fourty-seven  newly diagnosed MCL patients 
treated with induction chemotherapy followed by maintenance will be enrolled for this study. 
If 33 or more patients are being followed, alive and progression free at the end of the 3rd 
year, this treatment regimen will be declared effective. This decision rule has a type I error 
(declaring the new treatment regimen promising while it is actually not) less than 0.1 and a 
type II error (declaring the new treatment regimen not promising while it actually is) rate less 
than 0.2. 
The above decision rule is based upon an expected proportion of high-risk and low-risk 
patients of 65% and 35%, respectively. “High risk” patients are defined by Ki-67≥30% or 
blastic/blastoid/pleomorphic morphology. “Low risk” patients are those with Ki-67<30% and 
lack of blastic/blastoid/pleomorphic morphology. Of note, the “low risk” category defined here 
includes a combination of low and intermediate risk groups that were previously discussed in 
Section 2.0. Historical data predicts that the expected 3-year PFS of high-risk patients is 
approximately 50% whereas the expected 3-year PFS of low-risk patients is 75-80%. To 
ensure enrollment of the expected proportion of high-risk and low-risk patients and, 
therefore, ensure that the decision rule is appropriate, we will fix the number of high risk 
patients as 31 and the number of low risk patients as 16.  If the maximum number of patients 
has been enrolled for either the high risk group or low risk group, enrollment will continue 
only for group in which enrollment has not yet been met. 
If a patient is enrolled and unable to complete induction treatment, that patient will be 
replaced.   
We aim to enroll 47 patients in 1.5 years (accrual rate is 2-3 patients per month).  
Secondary Objectives: PFS and OS of treated patients (overall and in different clinical risk 
subgroups) will be evaluated by survival analysis tools such as Kaplan-Meier and compared 
by the log-rank test. The prognostic value of M-IPI on PFS and OS will be evaluated by 
survival regression models such as the Cox model. The rate of PET-negativity at various 
time points will be estimated by sample proportions and their confidence intervals will be 
computed. Their correlate with PFS will be evaluated by landmark Cox regression). MRD 
status at various time points will also be correlated with PFS using landmark Cox model.  
 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 43 of 50 
 
15.0 
 RESEARCH PARTICIPANT REGISTRATION AND RANDOMIZATION PROCEDURES 
15.1 
Research Participant Registration 
Confirm eligibility as defined in the section entitled Criteria for Patient/Subject Eligibility. 
Obtain informed consent, by following procedures defined in section entitled Informed 
Consent Procedures. 
During the registration process registering individuals will be required to complete a protocol 
specific Eligibility Checklist. 
All participants must be registered through the Clinical Trials Management System (CTMS) 
Office at Memorial Sloan Kettering Cancer Center. Registrations must be submitted via the 
CTMS Electronic Registraiton System (https://ctms.mskcc.org/forte-platform-web/login).  
15.2 
Randomization 
This is not a randomized trial. 
16.0 
DATA MANAGEMENT ISSUES 
A Research Study Assistant (RSA) will be assigned to the study. The responsibilities of the 
RSA include project compliance, data collection, abstraction and entry, data reporting, 
regulatory monitoring, problem resolution and prioritization, and coordination of the activities 
of the protocol study team.  
The data collected for this study will be entered into the Clinical Research Database (CRDB). 
Source documentation will be available to support the computerized patient record.  
Data to be collected will include:  
1. Patient demographics and related features:  
- age  
- sex  
2. Disease related features:  
- staging  
- disease risk classification (for example, international prognostic index)  
- disease status at follow-up 
- description of relapse 
3. Treatment related  
- type of treatment 
- duration of treatment  
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 44 of 50 
 
- response to treatment  
 
16.1 
Quality Assurance 
Registration reports will be generated to monitor patient accruals and completeness of 
registration data. Routine data quality reports will be generated to assess missing data and 
inconsistencies. Accrual rates and extent and accuracy of evaluations and follow-up will be 
monitored periodically throughout the study period and potential problems will be brought to 
the attention of the study team for discussion and action.  
Random-sample data quality and protocol compliance audits will be conducted by the study 
team, at a minimum of two times per year, more frequently if indicated.  
16.2 
Data and Safety Monitoring 
The Data and Safety Monitoring (DSM) Plans at Memorial Sloan-Kettering Cancer Center 
were approved by the National Cancer Institute in September 2001. The plans address the 
new policies set forth by the NCI in the document entitled “Policy of the National Cancer 
Institute for Data and Safety Monitoring of Clinical Trials” which can be found at 
http://www.cancer.gov/clinicaltrials/conducting/dsm-guidelines. The DSM Plans at MSKCC 
were established and are monitored by the Office of Clinical Research. The MSKCC Data 
and Safety Monitoring Plans can be found on the MSKCC Intranet at: 
http://inside2/clinresearch/Documents/MSKCC%20Data%20and%20Safety%20Monitoring%
20Plans.pdf 
There are several different mechanisms by which clinical trials are monitored for data, safety 
and quality. There are institutional processes in place for quality assurance (e.g., protocol 
monitoring, compliance and data verification audits, therapeutic response, and staff 
education on clinical research QA) and departmental procedures for quality control, plus 
there are two institutional committees that are responsible for monitoring the activities of our 
clinical trials programs. The committees: Data and Safety Monitoring Committee (DSMC) for 
Phase I and II clinical trials, and the Data and Safety Monitoring Board (DSMB) for Phase III 
clinical trials, report to the Center’s Research Council and Institutional Review Board.  
During the protocol development and review process, each protocol will be assessed for its 
level of risk and degree of monitoring required. Every type of protocol (e.g., NIH sponsored, 
in-house sponsored, industrial sponsored, NCI cooperative group, etc.) Will be addressed 
and the monitoring procedures will be established at the time of protocol activation. 
17.0 
PROTECTION OF HUMAN SUBJECTS 
MSKCC affirms the subject’s right to protection against invasion of privacy.  In compliance 
with United States federal regulations, Celgene requires the Investigator to permit 
representatives of Celgene Corporation and, when necessary, representatives of the FDA or 
other regulatory authorities to review and/or copy any medical records relevant to the study 
in accordance with local laws. 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 45 of 50 
 
Should direct access to medical records require a waiver or authorization separate from the 
subject’s statement of informed consent, it is the responsibility of the Investigator to obtain 
such permission in writing from the appropriate individual. 
17.1 
Privacy 
MSK’s Privacy Office may allow the use and disclosure of protected health information 
pursuant to a completed and signed Research Authorization form. The use and disclosure of 
protected health information will be limited to the individuals described in the Research 
Authorization form. A Research Authorization form must be completed by the Principal 
Investigator and approved by the IRB and Privacy Board (IRB/PB).  
The consent indicates that individualized de identified information collected for the purposes  
of this study may be shared with other qualified researchers. Only researchers who have  
received approval from MSK will be allowed to access this information which will not include  
protected health information, such as the participant’s name, except for dates. It is also  
stated in the Research Authorization that their research data may be shared with other  
qualified researchers. 
 
17.2 
Serious Adverse Event (SAE) Reporting 
 
 An adverse event is considered serious if it results in ANY of the following outcomes:  
 
Death  
 
A life-threatening adverse event  
 
An adverse event that results in inpatient hospitalization or prolongation of existing 
hospitalization A persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions  
 
A congenital anomaly/birth defect  
 
Important Medical Events (IME) that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based upon medical judgment, they may 
jeopardize the patient or participant and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition  
Note: Hospital admission for a planned procedure/disease treatment is not considered an SAE.  
 
SAE reporting is required as soon as the participant starts investigational treatment/intervention. 
SAE reporting is required for 30-days after the participant’s last investigational 
treatment/intervention. Any event that occur after the 30-day period that is unexpected and at least 
possibly related to protocol treatment must be reported.  
 
Please note: Any SAE that occurs prior to the start of investigational treatment/intervention and is 
related to a screening test or procedure (i.e., a screening biopsy) must be reported.  
 
All SAEs must be submitted in PIMS. If an SAE requires submission to the HRPP office per IRB 
SOP RR-408 ‘Reporting of Serious Adverse Events’, the SAE report must be submitted within 5 
calendar days of the event. All other SAEs must be submitted within 30 calendar days of the event.  
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 46 of 50 
 
 
The report should contain the following information:  
 
 
The date the adverse event occurred  
 
The adverse event  
 
The grade of the event  
 
Relationship of the adverse event to the treatment(s)  
 
If the AE was expected  
 
Detailed text that includes the following o An explanation of how the AE was handled  
 
A description of the participant’s condition  
 
Indication if the participant remains on the study  
 
If an amendment will need to be made to the protocol and/or consent form  
 
If the SAE is an Unanticipated Problem  
 
For IND/IDE protocols: The SAE report should be completed as per above instructions. If 
appropriate, the report will be forwarded to the FDA by the IND Office. 
 
17.2.1  
Not applicable 
18.0 
INFORMED CONSENT PROCEDURES 
Before protocol-specified procedures are carried out, consenting professionals will explain 
full details of the protocol and study procedures as well as the risks involved to participants 
prior to their inclusion in the study. Participants will also be informed that they are free to 
withdraw from the study at any time. All participants must sign an IRB/PB-approved consent 
form indicating their consent to participate. This consent form meets the requirements of the 
Code of Federal Regulations and the Institutional Review Board/Privacy Board of this Center. 
The consent form will include the following:  
1. The nature and objectives, potential risks and benefits of the intended study.  
2. The length of study and the likely follow-up required. 
3. Alternatives to the proposed study. (This will include available standard and 
investigational therapies. In addition, patients will be offered an option of supportive 
care for therapeutic studies.) 
4. The name of the investigator(s) responsible for the protocol. 
5. The right of the participant to accept or refuse study interventions/interactions and to 
withdraw from participation at any time.  
Before any protocol-specific procedures can be carried out, the consenting professional will 
fully explain the aspects of patient privacy concerning research specific information.  In 
addition to signing the IRB Informed Consent, all patients must agree to the Research 
Authorization component of the informed consent form. 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 47 of 50 
 
Each participant and consenting professional will sign the consent form. The participant must 
receive a copy of the signed informed consent form. 
 
 
 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 48 of 50 
 
19.0 
REFERENCES 
 
1. 
A clinical evaluation of the International Lymphoma Study Group classification of non-
Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-18, 1997 
 
2. 
Bernard M, Gressin R, Lefrere F, et al: Blastic variant of mantle cell lymphoma: a rare 
but highly aggressive subtype. Leukemia 15:1785-91, 2001 
 
3. 
Bosch F, Jares P, Campo E, et al: PRAD-1/cyclin D1 gene overexpression in chronic 
lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 84:2726-32, 
1994 
 
4. 
Wlodarska I, Dierickx D, Vanhentenrijk V, et al: Translocations targeting CCND2, 
CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 111:5683-90, 2008 
 
5. 
Salaverria I, Royo C, Carvajal-Cuenca A, et al: CCND2 rearrangements are the most 
frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 121:1394-402, 2013 
 
6. 
Fernandez V, Salamero O, Espinet B, et al: Genomic and gene expression profiling 
defines indolent forms of mantle cell lymphoma. Cancer Res 70:1408-18, 2010 
 
7. 
Mozos A, Royo C, Hartmann E, et al: SOX11 expression is highly specific for mantle 
cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 94:1555-62, 2009 
 
8. 
Hoster E, Dreyling M, Klapper W, et al: A new prognostic index (MIPI) for patients 
with advanced-stage mantle cell lymphoma. Blood 111:558-65, 2008 
 
9. 
Hoster E, Klapper W, Hermine O, et al: Confirmation of the mantle-cell lymphoma 
International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. 
J Clin Oncol 32:1338-46, 2014 
 
10. 
Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression 
signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell 
lymphoma. Cancer Cell 3:185-97, 2003 
 
11. 
Geisler CH, Kolstad A, Laurell A, et al: Long-term progression-free survival of mantle 
cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a 
nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687-93, 
2008 
 
12. 
Schaffel R, Hedvat CV, Teruya-Feldstein J, et al: Prognostic impact of proliferative 
index determined by quantitative image analysis and the International Prognostic Index in patients 
with mantle cell lymphoma. Ann Oncol 21:133-9, 2010 
 
13. 
Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable remissions after 
treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD 
alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-23, 
2005 
 
14. 
Romaguera JE, Fayad LE, Feng L, et al: Ten-year follow-up after intense 
chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose 
methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated 
aggressive mantle cell lymphoma. Br J Haematol 150:200-8, 2010 
 
15. 
Geisler CH, Kolstad A, Laurell A, et al: Nordic MCL2 trial update: six-year follow-up 
after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or 
BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J 
Haematol 158:355-62, 2012 
 
16. 
Delarue R, Haioun C, Ribrag V, et al: CHOP and DHAP plus rituximab followed by 
autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe 
d'Etude des Lymphomes de l'Adulte. Blood 121:48-53, 2013 
 
17. 
Hermine O, Hoster E, Walewski J, et al: Alternating Courses of 3x CHOP and 3x 
DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and 
Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 
Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in 
Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell 
Lymphoma Network (MCL net). Blood (ASH Annual Meeting Abstracts) 120:151, 2012 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 49 of 50 
 
 
18. 
Dredge K, Horsfall R, Robinson SP, et al: Orally administered lenalidomide (CC-
5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in 
vitro. Microvasc Res 69:56-63, 2005 
 
19. 
Corral LG, Haslett PA, Muller GW, et al: Differential cytokine modulation and T cell 
activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J 
Immunol 163:380-6, 1999 
 
20. 
Davies FE, Raje N, Hideshima T, et al: Thalidomide and immunomodulatory 
derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-6, 2001 
 
21. 
Wu A, Scheffler MR: Multiple-dose pharmacokinetics and safety of CC-5013 in 15 
multiple myeloma patients. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings 
22, 2004 
 
22. 
Zinzani PL, Vose JM, Czuczman MS, et al: Long-term follow-up of lenalidomide in 
relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 
24:2892-7, 2013 
 
23. 
Goy A, Sinha R, Williams ME, et al: Single-agent lenalidomide in patients with mantle-
cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 
(EMERGE) study. J Clin Oncol 31:3688-95, 2013 
 
24. 
Wang M, Fayad L, Wagner-Bartak N, et al: Lenalidomide in combination with 
rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. 
Lancet Oncol 13:716-23, 2012 
 
25. 
Ruan J, Martin P, Shah BD, et al: Combination Biologic Therapy Without 
Chemotherapy As Initial Treatment For Mantle Cell Lymphoma: Multi-Center Phase II Study Of 
Lenalidomide Plus Rituximab Blood (ASH Annual Meeting Abstracts), 2013 
 
26. 
Ruan GP, Martin P, Shah BD, et al: Sustained Remission with the Combination 
Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A 
Multi-Center Phase II Study Report. Blood (ASH Annual Meeting Abstracts) 124, 2014 
 
27. 
Chiappella A, Tucci A, Castellino A, et al: Lenalidomide plus cyclophosphamide, 
doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients 
with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. 
Haematologica 98:1732-8, 2013 
 
28. 
Nowakowski GS, LaPlant B, Habermann TM, et al: Lenalidomide can be safely 
combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: 
phase I study. Leukemia 25:1877-81, 2011 
 
29. 
Nowakowski GS, LaPlant B, Macon WR, et al: Lenalidomide Combined With R-CHOP 
Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly 
Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. J Clin Oncol, 2014 
 
30. 
Vitolo U, Chiappella A, Franceschetti S, et al: Lenalidomide plus R-CHOP21 in elderly 
patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, 
phase 2 trial. Lancet Oncol 15:730-7, 2014 
 
31. 
Fenske TS, Zhang MJ, Carreras J, et al: Autologous or reduced-intensity conditioning 
allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: 
analysis of transplantation timing and modality. J Clin Oncol 32:273-81, 2014 
 
32. 
Kluin-Nelemans HC, Hoster E, Hermine O, et al: Treatment of older patients with 
mantle-cell lymphoma. N Engl J Med 367:520-31, 2012 
 
33. 
Chang JE, Li H, Smith MR, et al: Phase 2 study of VcR-CVAD with maintenance 
rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study 
(E1405). Blood 123:1665-73, 2014 
 
34. 
Le Gouill S, Thieblemont C, Oberic L, et al: Rituximab Maintenance Versus Wait and 
Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in 
Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the 
Phase III Prospective Lyma Trial, a Lysa Study. ASH Annual Meeting Abstracts, 2014 
 
35. 
Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell 
transplantation for multiple myeloma. N Engl J Med 366:1782-91, 2012 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022


 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Page 50 of 50 
 
 
36. 
McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide after stem-cell 
transplantation for multiple myeloma. N Engl J Med 366:1770-81, 2012 
 
37. 
Faham M, Zheng J, Moorhead M, et al: Deep-sequencing approach for minimal 
residual disease detection in acute lymphoblastic leukemia. Blood 120:5173-80, 2012 
 
38. 
Armand P, Oki Y, Neuberg DS, et al: Detection of circulating tumour DNA in patients 
with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 163:123-6, 2013 
 
39. 
Pott C, Hoster E, Delfau-Larue MH, et al: Molecular remission is an independent 
predictor of clinical outcome in patients with mantle cell lymphoma after combined 
immunochemotherapy: a European MCL intergroup study. Blood 115:3215-23, 2010 
 
40. 
Kolstad A, Laurell A, Jerkeman M, et al: Nordic MCL3 study: 90Y-ibritumomab-
tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood 
123:2953-9, 2014 
 
41. 
Fowler NH, Nastoupil LJ, Hagemeister FB, et al: Characteristics and management of 
rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin 
lymphoma. Haematologica 100:e454-7, 2015 
 
42. 
Meignan M, Gallamini A, Haioun C: Report on the First International Workshop on 
Interim-PET-Scan in Lymphoma. Leuk Lymphoma 50:1257-60, 2009 
 
43. 
Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. 
Nephron 16:31-41, 1976 
 
44. 
Luke DR, Halstenson CE, Opsahl JA, et al: Validity of creatinine clearance estimates 
in the assessment of renal function. Clin Pharmacol Ther 48:503-8, 1990 
20.0 
APPENDICES 
Appendix 1. Sequenta Specimen Recommendation Sheet 
Appendix 2. Lenalidomide Pill Diary  
Appendix 3. Cockcroft-Gault estimation of creatinine clearance (CrCl) 
Cockcroft-Gault estimation of CrCl:43,44 
CrCl (mL/min) =  
    (140 –age) x (weight, kg)__           
   (Males) 
 
72 x (serum creatinine, mg/dL) 
 
CrCl (mL/min) =  
    (140 –age) x (weight, kg)_    x 0.85         
   (Females)  
72 x (serum creatinine, mg/dL) 
 
Memorial Sloan Kettering Cancer Center
IRB Number: 15-196 A(15)
Approval date: 17-Feb-2022